

DUKE UNIVERSITY MEDICAL CENTER  
**CURRICULUM VITAE**

**Name:** Gordon Ralph Corey, M.D.  
**Primary Academic Appointment:** Professor of Medicine & Infectious Diseases  
**Primary Academic Department:** Medicine  
**Present Academic rank and title:** Gary Hock Distinguished Professor of Global Health  
**Medical licensure:** NC 23109  
**Specialty Certification and dates:** Internal Medicine, 1977 & Infectious Diseases, 1980  
Clinical Tropical Medicine / Travelers' Health, 2000

**Education:**

High School	Evanston Township High, Evanston IL	1961-1965	Diploma
College	Duke University, Durham, NC	1966-1970	B.A., Physics
Medical School	Baylor College of Medicine, Houston TX	1970-1973	M.D.

**Scholarly societies:** Alpha Omega Alpha

**Professional training and academic career:**

1974 -1974 6 month externship, cardiology, Royal Postgraduate Medical School, London  
1974 -1975 Internship in Medicine, Duke University Medical Center  
1975 -1977 Residency in Medicine, Duke University Medical Center  
1977 -1978 Chief Resident in Medicine, Durham VAH, Duke University Medical Center  
1978 -1980 Fellowship in Infectious Disease, Duke University Medical Center  
1980 -1983 Instructor in Medicine, Durham VAH, Duke University Medical Center  
1983 - 1993 Assistant Professor of Medicine, Duke University Medical Center  
1984 - 2002 Director, Internal Medicine Residency Training Program, Duke University Medical Center  
1985 - 2002 Founder, Co-Director, Med/Ped Residency Training Program, Duke University Medical Center  
1993 -1998 Associate Professor of Medicine & Infectious Disease, Duke University Medical Center  
1999 - Present Professor of Medicine & Infectious Disease, Duke University Medical Center  
1985 -1989 Director, Graduate Medical Education, Duke University Medical Center  
1989 -1990 Associate Dean of GME, Duke University Medical Center  
1992 - 2002 Founder, Co-Director, Med/Psych Residency Training Program, Duke University Medical Center  
1994 - 1999 Founder, Co-Director, Med/Neuro Residency Training Program, Duke University Medical Center  
2005- 2012 Director, Infectious Disease Research, Duke Clinical Research Institute  
2005 – Present Director, Hubert-Yeargan Center for Global Health  
2011 – Present Vice Chair for Education and Global Health, Department of Medicine, Duke University Medical Center

## **Bibliography:**

### **Peer-Reviewed Manuscripts:**

1. Eknoyan G, **Corey GR**, Loomis J, Suki WN, Martinez-Maldonado M. Lithium-induced diabetes insipidus: Effects on urinary cyclic AMP excretion and renal tissue adenylate cyclase activity. Clin Res 21:524, 1974.
2. Durack DT, **Corey GR**, Perfect JR: Trimethoprim-sulfamethoxazole vs ampicillin in the treatment of experimental meningitis due to *Streptococcus pneumoniae*. Rev Inf Dis 1982 Mar-Apr;4:311-314. PMID:6981157
3. Mulrow CD, **Corey GR**: A painful swollen arm in a young woman. NC Med J 44:217-218, 1983. PMID:6574328
4. Mulrow CD, **Corey GR**, Brown JT: A look at the stool can save the barium study. NC Med J 44:309-310, 1983. PMID:6575265
5. Mulrow C, JT Brown, WB Lide, **GR Corey**: Herpetic Whitlow. NC Med J 44:312-313, 1983. PMID:6575265
6. Mulrow CD, Michels M, **Corey GR**, Brown JT: Cutaneous cholesterol embolism of the lower extremities. NC Med J 44:382-383, 1983. PMID:6576236
7. Cohen JI, Corson AP, **Corey GR**: Late appearance of skin rash in rocky mountain spotted fever. South Med J 76:1457-1458, 1983. PMID:6635747
8. Moorman JR, **Corey GR**: Distended neck veins. NC Med J 44:562-563, 1983. PMID:6579373
9. Svetkey LP, **Corey GR**: A chronically red eye. NC Med J 44:629-630, 1983. PMID:6580532
10. McDonald MI, **Corey GR**, Gallis HA, Durack DT: Single and multiple pyogenic liver abscesses: Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. Medicine 63:291-302, 1984. PMID:6472091
11. Cohen JI, **Corey GR**: Cytomegalovirus infection in the normal host. Medicine 64:100-114, 1985. PMID:2983175.
12. Mulrow CD, **Corey GR**: Pericardial pseudoeffusion due to steroid-induced lipomatosis. NC Med J 46:179-180, 1985. PMID:3856753.
13. Frazier LM, **Corey GR**: Acute bacterial sinusitis. NC Med J 47:115-117, 1986. PMID:3457281
14. Graham M, **Corey R**, Califf R, Phillips H. Isotretinoin and *Staphylococcus aureus* infection: A possible association. Arch Derm 122:815-817, 1986. PMID:3460532.

15. Cohen JI, Bartlett JA, **Corey GR**. Extra-intestinal manifestations of salmonella. *Medicine* 66:349-388, 1987. PMID:3306260
16. Williams C, **Corey R**. Neisseria gonorrhoea endocarditis on a prosthetic valve. *South Med J* 9:1194-1195, 1987.
17. **Corey R**, Hla KM. Major and massive hemoptysis: A reassessment of conservative management. *Am J Med Sci* 294-302:1987. PMID:3425580.
18. Gould B, **Corey R**. Fever with a dissecting aorta aneurysm. *NC Med J* 48:574-576, 1987. PMID:3480425.
19. Kraus WE, Valenstein PN, **Corey GR**: Purulent pericarditis caused by *Candida*: Report of three cases and identification of high-risk populations as an aid to early diagnosis. *Rev Infect Dis* 10:34-41, 1988. PMID:3162595
20. Blum F, **Corey R**: Jellyfish Envenomation. *NC Med J* 49:25-26, 1988
21. Wall TC, Peyton RB, **Corey GR**: Gonococcal Endocarditis: A New Look At An Old Disease. *Medicine* 68: 375-380, 1989. PMID:2509857
22. Kim JH, VanderHorst C, Mulrow CD, **Corey GR**: *Staphylococcus aureus* Meningitis: A Review of 28 Cases. *Rev Infect Dis*, 11:698-706, 1989. PMID:2682944.
23. Miller M, **Corey GR**, Neelon FA: Angiokeratoma of Fordyce. *NC Med J* 51:71, 1990. PMID:2407964.
24. Clyde WA Jr., TC Wall, CM O'Connor, RT Kenney, P Van Trigt, III, GB Hill, and **RC Corey**. *Mycoplasma pneumoniae* Pericarditis: Two Cases with Isolation of the Organism from Pericardial Fluid. BL. Suppl. 20, IN: Recent Advances in Mycoplasmology. Proceedings of the 7th Congress of the International Organization for Mycoplasmology, Baden near Vienna, 1988. G Stanek, GH Cassell, JG Tully, RF Whitcomb, eds. Gustav Fischer Verlag, Stuttgart, New York.1990.
25. Ingram CW, Nichole B, Martinez S and **Corey GR**. Gonococcal osteomyelitis: case report and review of the literature. *Arch Intern Med* 151: 177-179, 1991. PMID: 1985594.
26. Campbell PT, Van Trigt P, Wall TC, Kenney RT, O'Connor CM, Sheikh KH, Kisslo JA, Baker ME, **Corey GR**: Subxiphoid pericardiotomy in the diagnosis and management of large pericardial effusions associated with malignancy. *Chest* 101:938-943, 1992. PMID:1555467.
27. Wall TC, Campbell, PT, O'Conner CM, Van Trigt P, Kenney RT, Sheikh KH, Kisslo JA, **Corey GR**: Diagnosis and Management (by Subxiphoid Pericardiotomy) of Large Pericardial Effusions Causing Cardiac Tamponade. *Amer J Cardiol* 69:1075-1078, 1992. PMID: 1561981.

28. Woodyear WE, Campbell PT, and **Corey GR**. Not So "Good to the Last Drop" Ethylene Glycol Toxicity in a Coffee Consuming Camper. *NC Med J*. 53:134-136, 1992. Stoner BP and **Corey GR**. Chronic Fatigue Syndrome: An Overview. *NC Med J*. 53:267-270, 1992. PMID: 1594052
29. Sexton DJ, **Corey, GR**. Rocky Mountain Spotless and Almost Spotless Fever: A Wolf in Sheeps Clothing. *Clin Inf Dis*. 15:439-448, 1992. PMID: 1520791
30. St. Clair EW, Oddone EZ, Waugh RA, **Corey GR**, and Feussner, JR. Assessing Housestaff Diagnostic Skills Using a Cardiology Patient Simulator. *Ann Int Med*. 117: 751-756, 1992. PMID:1416578.
31. Lee JG, McLeod ME, **Corey GR**, Meyers WC, Author J. Successful laparoscopic management of perforated gallbladder associated with *Salmonella javiana* infection. *NC Med J*.53:594-595, 1992. PMID:1436154.
32. Crews JR, Harrison JK, **Corey GR**, Steenbergen C, Bashore TM. Stunned Myocardium in Toxic Shock Syndrome. *Annals Int Med*, 117:912-913, 1992. PMID:1443952.
33. Ingram CW, Durack DT, Kernodle GW, and **Corey GR**. Disseminated Infection caused by Rapidly Growing Mycobacterium. *Clin Inf Dis* 16:463-471, 1993. PMID:8513048.
34. Kenney RT, Li Jennifer, Wallace AC Jr., Wall TC, O'Connor CM, Campbell PT, Van Tright P, and **Corey GR**. Mycoplasma Pericarditis. Evidence for Invasive Disease. *Clin Inf Dis*, 17 (Suppl 1)S58-62, 1993. PMID:8399939.
35. **Corey RC**, Campbell PT, Van Trigt P, Kenney RT, O'Connor C, Sheikh KH, Kisslo JA, Wall TC. Etiology of Large Pericardial Effusions. *American Journal of Medicine*. 95(2):209-213, August 1993. PMID:8356985.
36. Oddone EZ, Waugh RA, Samsa G, **Corey GR**, and Feussner, RJ. Teaching Cardiovascular Examination Skills: Results From a Randomized Controlled Trial. *American Journal of Medicine* 95(4): 389-396, October 1993. PMID:8213871.
37. Sexton DJ, Muniz M, **Corey GR**, Breitschwerdt L, Hegerty B, Dumler S, Walker DH, Pecanha PM, and Dietze R. Brazilian Spotted Fever in Espirito Santo, Brazil: Description of a Focus of Infection in a New Endemic Region. *Am J Trop Med Hyg* 49: 222-226, 1993. PMID:8357085.
38. Sexton DJ, Heskestad L, Lambeth WR, McCallum R, Levin LS, **Corey GR**. Postoperative Pubic Osteomyelitis Misdiagnosed as Osteitis Publis. Report of Four Cases and Review. *Clin Inf Dis* 17: 695-700, 1993. PMID:8268352.
39. Van Trigt P, Smith PK, Douglas JM, Campbell PT, Wall TC, Kenney RT, O'Connor CM, **Corey, GR**: A prospective trial of subxiphoid pericardiectomy in the diagnosis and treatment of large

pericardial effusion: A follow-up report. *Annals of Surgery* 218: 777-782, 1993. PMID:8257228.

40. Durack DT, Lukes AD, Bright DK, Duke Endocarditis Service. New Criteria for Diagnosis of Infective Endocarditis: Utilization of Specific Echocardiographic Findings. *Am J Med* 96: 200-209, 1994. PMID:8154507.
41. Thel MC, Ciaccia D, Vredenbrugh JJ, Peters W, & **Corey GR**. *Clostridium septicum* abscess in hepatic metastases: successful medical management. *Bone Marrow Transplantation* 13: 495-496, 1994. PMID:7517261.
42. Darling TN, Sidhu-Malik N, **Corey GR**, Allen NB, Kamino H, Murray JC. Treatment of *Mycobacterium haemophilum* Infection with an Antibiotic Regimen including Clarithromycin. *Brit. J. Derm.* 131: 376-379, 1994. PMID:7918014.
43. Luttrell LM, Kanj SS, **Corey GR**, Lins RE, Spinner RJ, Mallon WJ, Sexton DJ. *Mycoplasma hominis* Septic arthritis: Two Case Reports and Review. *Clin Infect Dis* 19: 1067-1070, 1994. PMID:7888535.
44. Sexton DJ, Kanj SS, Wilson K, **Corey GR**, Hegarty BC, Levy MG, Breitschwerdt EB. The Use of Polymerase Chain Reaction as a Diagnostic Test for Rocky Mountain Spotted Fever. *Am J Trop Med & Hygiene*, 50: 59-63, 1994. PMID:8304573.
45. Dietze R, Perkins M, Boulos M, Luz FCO, Reller B, **Corey GR**. The Diagnosis of *Plasmodium falciparum* Infection Using a New Antigen Detection System. *Am J Trop Med Hgy* 52 45-49, 1995. PMID:7856824.
46. Campbell PT, Li JS, Wall TC, O'Connor CM, Van Tright P, Kenney RT, and Melhus O, **Corey GR**. Cytomegalovirus Pericarditis: A Case Series and Review of the Literature. *Am J Med Sci* 309(4):229-234, 1995. PMID:7900747.
47. Miller WC, **Corey GR**, Lallinger GJ, Durack DT. International Health and Internal Medicine Residency Training: The Duke University Experience. *Am J Med* 99: 291-297, 1995. PMID:7653490.
48. Sexton, DJ, **Corey GR**, Ingram CW, Morris VM, Haywood HB. Consultation in university-based and community based infectious disease practice: a prospective study. *Clin Infect Dis* 20:391-393, 1995. PMID:7742446.
49. Dodds AG, Abramson MA, **Corey GR**, Kisslo J, Sexton DJ. Use of the Duke Criteria for the Diagnosis of Infective Endocarditis (let) *Clin Infect Dis* 21(2):448-449, 1995. PMID:8562766.
50. Dietze R, Boulos M, **Corey GR**. Diagnosis of Canine Visceral Leishmaniasis with a Dot-Enzyme-Linked Immunosorbent Assay. *Am Soc Trop Med & Hyg* 53(1): 40-42, 1995. PMID:7625531.

51. Abolnik I, **Corey GR**. Pinning Down Infectious endocarditis. *Emergency Med.* 28: 85-90, 1995.
52. Kirkland KB, Li JS, Kenney RT, **Corey GR**. Pericarditis Due to MAI in an Immunocompetent Host. *Infect Dis Clin Pract* 5: 204-205, 1996.
53. Dodds GA, Sexton DJ, Durack DT, Bashore TM, **Corey GR**, Kisslo J, and the Duke Endocarditis Service. Negative Predictive Value of the Duke Criteria for Infective Endocarditis. *Am J Cardiol* 77(5):403-407, 1996. PMID:8602571.
54. Weinstein JW, Roe M, Towns M, Sanders L, Thorpe, JJ, **Corey GR**, Sexton DJ. Resistant Enterococci: A Prospective Study of Prevalence, Incidence, and Factors Associated with Colonization in a University Hospital. *Infect Control and Hosp Epidemiol* 17:36-41, 1996. PMID:8789685.
55. Sexton DJ, Rollin PE, Breitschewerdt EK, **Corey GR**, Myers SA, Dumais MR, Bowen MD, Goldsmith MGS, Zaki SR, Nichol ST, Peters CJ, Ksiazek TG. Life-Threatening Cache Valley Virus Infection. *N Eng J Med* 336: 547-549, 1997. PMID:9023091.
56. Marr KA, Sexton DJ, Conlon PJ, **Corey GR**, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. *Annals of Internal Medicine.* 127(4): 275-280, August 15, 1997. PMID:9265426.
57. Fowler VG, Li J, **Corey GR**, Boley J, Marr KA, Gopal AJ, Long LK, Gottlieb G, Donovan CL, Sexton DJ, Ryan T. Role of echocardiography in evaluation of patients with *Staphylococcus aureus* bacteremia: Experience with 103 patients. *J Am Coll Cardiol* 30: 1072-1078, 1997. PMID:9316542.
58. Robinson DL, Fowler VG, Sexton DJ, **Corey GR**, Conlon PJ. Bacterial endocarditis in hemodialysis patients. *Am J Kidney Dis* 30: 521-524, 1997. PMID:9328367.
59. Dietze R, Barros GB, Teixeira L, Harris J, Michelson K, Falqueto A, **Corey R**. The Effect of Eliminating Seropositive Canines on the Transmission of Visceral Leishmaniasis in Brazil. *Clin Infect Dis* 25: 1240-1242, 1997. PMID:9402389.
60. Meredith FT, Fowler VG, Gautier M, **Corey GR**, Reller LB. Bacillus cereus necrotizing Cellulitis Mimicking Clostridial Myonecrosis: Case report and review of the Literature. *Scandinavian Journal of Infectious Diseases* 29(5): 528-529, 1997. PMID:9435050.
61. Nettles RE, **Corey GR**, Li J, Sexton DJ. Evaluation of the Duke criteria in patients with prosthetic valve endocarditis. *Clin Infect Dis* 25:1401-3, 1997. PMID:9431386.
62. Conlon PJ, Jeffries F, Krigman HR, **Corey GR**, Sexton DJ, Abramson M. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. *Clin Nephrol* 49(2): 96-101, Feb. 1998. PMID:9524779.

63. Sexton, DJ, **Corey, GR**, Carpenter, C, Kong, LQ, Gandhi, T, Breitschwerdt, E, Hegarty, B, Chen, SM, Feng, HM, YU, XJ, Olano, J, Walker, DH, Dumler, SJ. Dual infection with Ehrlichia chaffeensis and a spotted fever group rickettsia: a case report. Emerging Infectious Diseases. 4(2): 311-6, Apr – Jun. 1998. PMID:9621205.
64. Gagliardi, JP, Nettles, RE, McCarty, DE, Sanders, LL, **Corey, GR**, Sexton, DJ. Native valve infective endocarditis in elderly and younger adult patients: comparison of clinical features and outcomes with use of the Duke criteria and the Duke Endocarditis Database. Clinical Infectious Diseases. 26(5): 1165-8, May 1998. PMID:9597246.
65. Fowler Jr., VG, Xanthakos S, **Corey GR**. Of Hogs and Men: A review of the Potential Infectious Health Risks posed by the Hog Industry in North Carolina. NCMJ 59: 12-15, 1998. PMID:9455131.
66. Marr KA, Fowler VG, Gopal A, Sexton DJ, Conlon PJ, and **Corey GR**. Incidence and Outcome of *Staphylococcus aureus* Bacteremia in hemodialysis patients. Kidney International 54(5):1684-1689, November 1998. PMID:9844145.
67. Fowler VG Jr., Sanders LL, Sexton DJ, Kong LK, Marr KA, Gopal AK, Gottlieb G, McClelland RS, **Corey GR**. Outcome of *Staphylococcus aureus* bacteremia according to compliance with infectious diseases specialist recommendations: experience with 244 patients. Clin Infect Dis 27:478-486, 1998. PMID:9770144.
68. Fowler VG Jr, Nacinovich FM, Alspaugh JA, **Corey GR**. Prosthetic joint infection with Histoplasma capsulatum: Case Report and Review. Clin Infect Dis 26: 1017, 1998. PMID:9564509.
69. Bayer AS, Cheng D, Yeaman MR, **Corey GR**, McClelland RS, Harrel E, Fowler VG. In Vitro Resistance to Thrombin-Induced Platelet Microbicidal Protein Among Clinical Bacteremic Isolates of *Staphylococcus aureus* Correlates with an Endovascular Infectious Source. Antimicrobial Agents & Chemotherapy. 42(12): 3169-72, 1998 Dec. PMID:9835510.
70. Hunt E, Hader SL, Files D, **Corey GR**. Arsenic poisoning seen at Duke Hospital, 1965-1998. North Carolina Medical Journal. 60(2):70-4, Mar–Apr. 1999. PMID:1344130.
71. Rosen, AB, Fowler, VG, Jr., **Corey, GR**, Downs, SM, Biddle, AK, Li, J, Jollis, JG. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Annals of Internal Medicine. 130(10): 810-20, May 18, 1999. PMID:10366370.
72. Dietze R, Fowler, VG, Jr., Steiner, TS, Pecanha, PM, **Corey, GR**. Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis. Am J Trop Med Hyg; 1999 May; 60(5): 837-9. PMID:10344661.

73. Carpenter, CF, Gandhi, TK, Kong, LK, **Corey, GR**, Chen, SM, Walker, DH, Dumler, JS, Breitschwerdt R, Hegarty, B, Sexton, DJ. The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina. *Journal of Infectious Diseases*. 180(3): 900-3, Sept. 1999. PMID:10438390.
74. Gopal AK, Whitehouse, JD, Simel, DL, **Corey, GR**. Cranial computed tomography before lumbar puncture: a prospective clinical evaluation. *Archives of Internal Medicine*. 159 (22): 2681-5, Dec 13-27, 1999. PMID:10597758.
75. Moff SI, **Corey, GR**, Gottfredsson, M. Distant cutaneous granulomas after bacille Calmette-Guerin immunotherapy for malignant melanoma: case for direct infection. *Clinical Infectious Diseases*. 29(6): 1569-70, Dec. 1999. PMID:10585816.
76. Sexton DJ, **Corey GR**, Greenfield JC Jr, Burton CS. Imported African tick-bite fever: a case report. *Am J Trop Med Hyg* 1999 May;60: 865-867. PMID:10344666.
77. McClelland RS, Fowler VG, Sanders LL, Gottlieb G, Kong LK, Sexton DJ, Schmader K, Lanclos KD, **Corey GR**. Staphylococcus aureus bacteremia among elderly vs young adult patients. Comparison of clinical features and mortality. *Arch Int Med* 159:1244-1247, June 14, 1999. PMID:10371233.
78. Fowler VG Jr., Kong LK, **Corey GR**, Gottlieb G, McClelland RS, Sexton DJ, Harrell LJ. Recurrent *Staphylococcus aureus* Bacteremia: Pulsed-Field Gel Electrophoresis Findings in 29 Consecutive Patients. *J Inf Dis* 79:1157-61, 1999. PMID:10191218.
79. Fowler Jr, VG, Sanders L, Kong LK, McClelland RS, Gottlieb G, Li J, Ryan T, Sexton DJ, Roussakis G, Harrell LJ and **Corey GR**. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. *Clin Infect Dis* 28:106-14, 1999. PMID:10028079
80. Abolnik IZ, Fahhoum JS, Cleveland KO, Abramson MA, **Corey GR**, Gelfand MS, Sexton DJ. Nosocomial Fever of Unknown Origin. *Infect. Dis Clin Prac*. 8:396-398, 1999.
81. Chamis AL, Gesty-Palmer D, Fowler VG, Corey GR. Echocardiography for the diagnosis of Staphylococcus aureus Infective Endocarditis. *Curr Infect Dis Resp*. 1999 Jun;1(2):129-135. PMID:11095778.
82. Gottlieb G, Fowler VG Jr., Kong LK, McClelland RS, Marr K, Gopal AK, Glower D, Sexton DJ, **Corey GR**. Staphylococcus aureus Bacteremia in the Postoperative Patient: a Prospective Analysis of 73 Consecutive Patients with Follow-up. *J Am Coll Surg*. 190 (1):50-7, 2000. PMID:10625232.
83. Gopal AK, Fowler VG Jr., Shah M, Gesty-Palmer D, Marr KA, McClelland RS, Kong LK, Gottlieb GS, Lanclos K, Li J, Sexton DJ, **Corey GR**. Prospective Analysis of *Staphylococcus aureas* Bacteremia in Nonneutropenic Adults with Malignancy. *J Clin Oncol*. 18(5):1110-1115, Mar 2000. PMID:10694564.



84. Fowler, VG Jr., McIntyre, LM, Yearman, MR, Peterson, GE, Barth Reller L., **Corey, GR**, Wray, D, Bayer, AS. In vitro resistance to thrombin-induced platelet microbicidal protein in isolates of *Staphylococcus aureus* from endocarditis patients correlates with an intravascular device source. *Journal of Infectious Diseases*. 182(4): 1251-4, Oct. 2000. PMID:10979928.
85. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr., Ryan T, Bashore T, **Corey GR**. Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis. *Clin. Infect. Dis*. 30(4): 633-8, 2000. PMID:10770721.
86. King JAC, Culpepper RM, **Corey GR**, Tucker JA, Lajoie G, Howell DN. Glomerulopathies with Fibrillary Deposits. *Ultrastructural Pathology* 24:15-21, 2000. PMID:10721148.
87. Roe, MT, Abramson, MA, Li, J, Heinle, SK, Kisslo, J, **Corey, GR**, Sexton, DJ. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the duke criteria. *American Heart Journal*.139(6): 945-51, Jun 2000. PMID:10827373.
88. Murdoch, DR, Roberts, SA, Fowler, VG, Jr., Shah, MA, Taylor, SL, Morris, AJ, **Corey, GR**. Infection of orthopedic prostheses after *Staphylococcus aureus* bacteremia. *Clinical Infectious Diseases*. 32(4): 647-9, Feb. 15, 2001. PMID:11181131.
89. Miller DL, Brazer S, Murdoch D, Reller LB, **Corey GR**. The Significance of *Clostridium Teritium* Bacteremia in Neutropenic and Nonneutropenic Patients: A Review of 32 Cases. *Clinical Infectious Diseases*. 32(6): 975-8, March 15, 2001. PMID: 11247721.
90. Fowler, VG Jr., Fey, PD, Reller, LB, Chamis, AL, **Corey, GR**, Rupp, ME. The intercellular adhesin locus *ica* is present in clinical isolates of *Staphylococcus aureus* from bacteremia patients with infected and uninfected prosthetic joints. *Medical Microbiology & Immunology* 189(3): 127-31, April 2001. PMID:11388609.
91. Cabell, CH, Pond, KK, Peterson, GE, Durack, DT, **Corey, GR**, Anderson, DJ, Ryan, T, Lukes, AS, Sexton, DJ. The risk of stroke and death in patients with aortic and mitral valve endocarditis. *American Heart Journal*. 142(1):75-80, Jul 2001. PMID:11431660.
92. Chamis, AL, Cabell, CH, Peterson, GE, **Corey, GR**, Sorrentino, RA, Ryan, T, Reller LB, Fowler, VG Jr. *Staphylococcus aureus* bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. *Circulation*. 104(9): 1029-33, Aug. 28, 2001. PMID:11524397.
93. Meine, TJ, Nettles, RE, Anderson, DJ, Cabell, CH, **Corey, GR**, Sexton, DJ, Wang, A. Cardiac conduction abnormalities in endocarditis defined by the Duke criteria. *American Heart Journal*. 142(2):280-5, Aug. 2001. PMID:11479467.

94. Cabell, Christopher H. MD 1; Schardt, Connie MLS; Sanders, Linda MPH; **Corey, G. Ralph** MD; Keitz, Sheri A. MD, PhD. Resident Utilization of Information Technology: A Randomized Trial of Clinical Question Formation. *Journal of General Internal Medicine*. 16(12):838-844, December 2001. PMID:11903763.
95. Cabell, Christopher H. MD; Jollis, James G. MD; Peterson, Gail E. MD; **Corey, G. Ralph** MD; Anderson, Deverick J. MD; Sexton, Daniel J. MD; Woods, Christopher W. MD; Reller, L; Ryan, Thomas MD; Fowler, Vance G. Jr MD, MHS Changing Patient Characteristics and the Effect on Mortality in Endocarditis. *Archives of Internal Medicine*. 162(1):90-94, January 14, 2002. PMID:11784225.
96. Shah MA, Sanders L, Wray D, Lanclos K, Chamis AL, **Corey GR**, Gockerman J, Fowler VG Jr. *Staphylococcus Aureus* Bacteremia in Patients with Neutropenia. *South Med J* 2002 Jul;95(7):782-84. PMID:12144094.
97. Fowler, V., Kaye, K., Simel, D., Cabell, C., McClachlan, D., Smith, P., Levin, S., Sexton, D., Reller, B., **Corey, GR.**, Oddone, E. Staphylococcus aureus Bacteremia following Median Sternotomy: Clinical Utility of Blood Culture Results in the Identification of Postoperative Mediastinitis. *Circulation* 2003; 108:73-78. PMID:12821547.
98. Anderson JD, Goldstein LB, Wilkinson WE, **Corey GR**, Cabel CH, Sanders LL, Sexton DJ. Stroke location, characterization, severity, and outcome in mitral vs/aortic valve endocarditis. *Neurology*. 2003; 61(10):1341-1346. PMID:14638952.
99. Fowler, Vance G. Jr MD, MHS; Olsen, Maren K. PhD; **Corey, G. Ralph** MD; Woods, Christopher W. MD, MPH; Cabell, Christopher H. MD; Reller, L. Barth MD; Cheng, Allen C. MB, BS; Dudley, Tara MS; Oddone, Eugene Z. MD, MHS Clinical Identifiers of Complicated *Staphylococcus aureus* Bacteremia. *Archives of Internal Medicine*. 163(17):2006-2072, September 22, 2003. PMID:14504120.
100. Jin, Tao; Bokarewa, Maria; McIntyre, Lauren; Tarowski, Andrej; **Corey, G. Ralph**; Reller, L Barth; Fowler, Vance G Jr Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient *Staphylococcus aureus* strains. *Journal of Medical Microbiology*. 52(10): 19-923, October 2003. PMID:12972589.
101. Levy, PY, **Corey, R**, Berger, P, Habib, G, Bonnet, JL, Levy, S, Messana, T, Dyiane, P, Frances, Yves, Botta, C, DeMicco, P, Dumon, H, Mundler, O, Chomel, JJ, Raoult, D. Etiologic Diagnosis of 204 Pericardial Effusions. *Medicine*, Nov 2003; 82: 385-7. PMID:14663288.
102. Anderson DJ, Murdoch DR, Sexton DJ, Reller LB, Stout JE, Cabell CH, **Corey GR**. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. *Infection*. 2004; 32(2):72-7. PMID:15057570.
103. Fowler, V., Sakoulas, G., McIntyre, L., Raman, V., Arbeit, R., Cabell, C., Stryjewski, M.,

Eliopoulos, G., Reller, B., **Corey, R.**, Jones, T., Lucindo, N., Yeaman, M., Bayer, A. Persistent bacteremia due to methicillin-resistant *Staphylococcus aureus* infection is associated with agr dysfunction and low-level invitro resistance to thrombin-induced platelet microbicidal protein. *Journal of Infectious Disease* 2004, 190(6):1140-1149. PMID:15319865.

104. Patel Manesh, Thomson Louise, Meine Trip, Burfeind William, Messier Robert, Robinson Edward, **Corey G Ralph**, Kim Raymond. Brief Case Report: An intra-cardiac mass in young man with congenitally acquired HIV. *Cardiology in Review* 12(3):126-130, May/June 2004. PMID:15078579.
105. Califf, Robert m. MD; Fowler, Vance Jr. MD, MHS; Cabell, Christopher H. MD; **Corey, G. Ralph** MD; Novel approaches to clinical trials; Devise-related infections. *American Heart Journal*. 147(4): 599-604, April 2004. PMID:15077074.
106. Cabell, Christopher H. MD; Heidenreich, Paul A. MD, MSc; Chu, Vivian H. MD; Moore, Christopher M. BS; Stryjewski, Martin E. MD; **Corey, G. Ralph** MD; Fowler, Vance G. Jr. MD, MHS. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. *American Heart Journal*. 147 (4): 582-586, April 2004. PMID:15077071.
107. Chu, Vivian H. MD Cabell, Christopher H. MD; Benjamin, Daniel K. Jr MD, MPH, PhD; Kuniholm, Erin F. MD, MPH; Fowler, Vance G. Jr MD, MHS; Engemann, John MD; Sexton, Daniel J. MD; **Corey, GR** MD; Wang, Andrew MD. Early Predictors of In-Hospital Death in Infective Endocarditis . *Circulation* 109(14):1745-1749, April 13, 2004. PMID:15037538.
108. C Chirouze, CH Cabell, VG Fowler Jr, N Khayat, L Olaison, JM Miro, G Habib, E Abrutyn, S Eykyn, **GR Corey**, C Selton-Suty, B Hoen, and International Collaboration on Endocarditis Study Group Prognostic factors in 61 cases of *Staphylococcus aureus* prosthetic valve infection endocarditis from the International Collaboration on Endocarditis merged database. *Clin Infect Dis* 1 May 2004 38 (9): p.1323. PMID:15127349.
109. Benjamin DK, Jr. Miro JM, Hoen B, Steinbach WJ, Fowler VG Jr, Olaison L, Habib G, Abrutyn E. Perfect J, Zass A, **Corey GR**, Eykyn S, Thuny F, Jimenez-Exposito MJ, Cabell CH, International Collaboration on Endocarditis Merged Database Study Group. Candida endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-mD). *Scandinavian Journal of Infectious Diseases*. 36(6-7):453-5, 2004. PMID:15307567.
110. Fowler VG Jr. Sakoulas G. McIntyre LM. Meka VG. Arbeit RD. Cabell CH. Stryjewski ME. Eliopoulos GM. Reller LB. **Corey GR**. Jones T. Lucindo N. Yeaman MR. Bayer AS. Persistent bacteremia due to methicillin-resistant *Staphylococcus aureus* infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. [Journal Article. Research Support, U.S. Gov't, P.H.S.] *Journal of Infectious Diseases*. 190(6):1140-9, 2004 Sep 15. PMID:15319865.

111. Jimenez-Exposito MJ. Torres G. Baraldes A. Benito N. Marco F. Pare JC. Moreno A. Claramonte X. Mestres CA. Almela M. Garcia de la Maria C. Perez N. Schell WA. **Corey GR**. Perfect J. Jimenez de Anta MT. Gatell JM. Miro JM. Native valve endocarditis due to *Candida glabrata* treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. *Clinical Infectious Diseases*. 39(7):e70-3, 2004 Oct 1. PMID:15472836.
112. Chu VH. Cabell CH. Abrutyn E. **Corey GR**. Hoen B. Miro JM. Olaison L. Stryjewski ME. Pappas P. Anstrom KJ. Eykyn S. Habib G. Benito N. Fowler VG Jr. International Collaboration on Endocarditis Merged Database Study Group. Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. *Clinical Infectious Diseases*. 39(10):1527-30, 2004 Nov 15. PMID:15546091.
113. Anguera I, Miro JM, Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, Olaison L, Pappas PA, de Lazzari E, Eykyn S, Habib G, Pare C, Wang A, **Corey GR**; ICE-MD investigators. Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the International Collaboration on Endocarditis Merged Database. *Am J Card* 2005 Oct 1; 96(7):976-81. PMID:16188527.
114. Hoen B. Chirouze C. Cabell CH. Selton-Suty C. Duchene F. Olaison L. Miro JM. Habib G. Abrutyn E. Eykyn S. Bernard Y. Marco F. **Corey GR**. International Collaboration on Endocarditis Study Group. Emergence of endocarditis due to group D streptococci: findings derived from the merged database of the International Collaboration on Endocarditis. *European Journal of Clinical Microbiology & Infectious Diseases*. 24(1):12-6, 2005 Jan. PMID:15660254.
115. Valente AM. Jain R. Scheurer M. Fowler VG Jr. **Corey GR**. Bengur AR. Sanders S. Li JS. Frequency of infective endocarditis among infants and children with *Staphylococcus aureus* bacteremia. [Journal Article] *Pediatrics*. 115(1):e15-9, 2005 Jan. PMID:15601815.
116. Reed SD. Friedman JY. Engemann JJ. Griffiths RI. Anstrom KJ. Kaye KS. Stryjewski ME. Szczech LA. Reller LB. **Corey GR**. Schulman KA. Fowler VG Jr. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible *Staphylococcus aureus* bacteremia. *Infection Control & Hospital Epidemiology*. 26(2):175-83, 2005 Feb. PMID:15756889.
117. El-Ahdab F. Benjamin DK Jr. Wang A. Cabell CH. Chu VH. Stryjewski ME. **Corey GR**. Sexton DJ. Reller LB. Fowler VG Jr. Risk of endocarditis among patients with prosthetic valves and *Staphylococcus aureus* bacteremia. [Journal Article. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] *American Journal of Medicine*. 118(3):225-9, 2005 Mar. PMID:15745719.
118. Fowler VG Jr. Justice A. Moore C. Benjamin DK Jr. Woods CW. Campbell S. Reller LB. **Corey GR**. Day NP. Peacock SJ. Risk factors for hematogenous complications of intravascular catheter-associated *Staphylococcus aureus* bacteremia. [Journal Article. Research Support, N.I.H.,

Extramural. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] *Clinical Infectious Diseases*. 40(5):695-703, 2005 Mar 1. PMID:15714415.

119. Bratton, R, **Corey, GR**. Tick-Borne Disease. *American Family Physician*. 2005 June 15; 71(12):2323-2330.
120. Stryjewski ME. O'Riordan WD. Lau WK. Pien FD. Dunbar LM. Vallee M. Fowler VG Jr. Chu VH. Spencer E. Barriere SL. Kitt MM. Cabell CH. **Corey GR**. FAST Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. [Clinical Trial, Phase II. Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] *Clinical Infectious Diseases*. 40(11):1601-7, 2005 Jun 1. PMID:15889357.
121. Engemann JJ. Friedman JY. Reed SD. Griffiths RI. Szczech LA. Kaye KS. Stryjewski ME. Reller LB. Schulman KA. **Corey GR**. Fowler VG Jr. Clinical outcomes and costs due to *Staphylococcus aureus* bacteremia among patients receiving long-term hemodialysis. [Journal Article. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] *Infection Control & Hospital Epidemiology*. 26(6):534-9, 2005 Jun. PMID:16018428.
122. Lalani, T, **Corey, GR**. Infective Endocarditis: Prevention, Diagnosis, and Treatment. *Infections in Medicine* 22, 251, June 2005.
123. Fowler, VG, Jr, Miro JM, Spelman D, Cabell CH, **Corey GR**, Hoen B, Abrutyn E, Chen A, Bradley S, van der Meer JTM, Elliott T, Jones P, Levine D, Athan E, Marco F, Bayer AS. *Staphylococcus aureus* Endocarditis throughout the World: A Product of Medical Progress. Report from the ICE Investigators. *JAMA*. 293(24):3012-21, 2005 Jun 22. PMID:15972563.
124. Heitner JF. Curtis JP. Haq SA. **Corey GR**. Newby LK. Jollis JG. The significance of elevated troponin T in patients with nondialysis-dependent renal insufficiency: a validation with coronary angiography. *Clinical Cardiology*. 28(7):333-6, 2005 Jul. PMID:16075826.
125. McDonald JR. Olaison L. Anderson DJ. Hoen B. Miro JM. Eykyn S. Abrutyn E. Fowler VG Jr. Habib G. Selton-Suty C. Pappas PA. Cabell CH. **Corey GR**. Marco F. Sexton DJ. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. [Comparative Study. Journal Article. Multicenter Study. Research Support, N.I.H., Extramural. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] *American Journal of Medicine*. 118(7):759-66, 2005 Jul. PMID:15989910.
126. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, **Corey GR**, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VG. *Staphylococcus aureus* native valve infective endocarditis: Report of 566 episodes from the International Collaboration on Endocarditis Merged database (ICE-MD). *CID* 41(4):507-14, 2005 Aug 15. PMID:16028160.
127. Vivian H. Chu MD<sup>1,2</sup>, Daniel J. Sexton MD<sup>1</sup>, Christopher H. Cabell MD MHS<sup>1,2</sup>, L. Barth

Reller MD<sup>1,4</sup>, Paul A. Pappas MS<sup>2</sup>, Rakesh K. Singh MD<sup>3</sup>, Vance G. Fowler, Jr, MD MHS<sup>1,2</sup>, **G. Ralph Corey MD<sup>1,2</sup>**, Olcay Aksoy BS<sup>3</sup>, Christopher W. Woods MD MPH<sup>1,2,5</sup>. Repeat Episodes of Endocarditis: Differentiating Relapse from Reinfection. *Clinical Infectious Diseases*. 41(3):406-9, 2005 Aug 1. PMID:16007540.

128. Fowler VG Jr. O'Brien SM. Muhlbaier LH. **Corey GR**. Ferguson TB. Peterson ED. Clinical predictors of major infections after cardiac surgery. [Journal Article. Research Support, N.I.H., Extramural. Research Support, U.S. Gov't, P.H.S.. Validation Studies] *Circulation*. 112(9 Suppl):I358-65, 2005 Aug 30. PMID:16159846.
129. Anderson DJ. Olaison L. McDonald JR. Miro JM. Hoen B. Selton-Suty C. Doco-Lecompte T. Abrutyn E. Habib G. Eykyn S. Pappas PA. Fowler VG. Sexton DJ. Almela M. **Corey GR**. Cabell CH. Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from the International Collaboration on Endocarditis-merged database. *European Journal of Clinical Microbiology & Infectious Diseases*. 24(10):665-70, 2005 Oct. PMID:16244853.
130. Steinbach WJ. Perfect JR. Cabell CH. Fowler VG. **Corey GR**. Li JS. Zaas AK. Benjamin DK Jr. A meta-analysis of medical versus surgical therapy for *Candida* endocarditis. [Journal Article. Meta-Analysis. Research Support, N.I.H., Extramural. Research Support, U.S. Gov't, P.H.S.] *Journal of Infection*. 51(3):230-47, 2005 Oct. PMID:16230221.
131. Cabell CH. Abrutyn E. Fowler VG Jr. Hoen B. Miro JM. **Corey GR**. Olaison L. Pappas P. Anstrom KJ. Stafford JA. Eykyn S. Habib G. Mestres CA. Wang A. International Collaboration on Endocarditis Merged Database (ICE-MD) Study Group Investigators. Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database. *American Heart Journal*. 150(5):1092-8, 2005 Nov. PMID:16291004.
132. Wang A. Pappas P. Anstrom KJ. Abrutyn E. Fowler VG Jr. Hoen B. Miro JM. **Corey GR**. Olaison L. Stafford JA. Mestres CA. Cabell CH. International Collaboration on Endocarditis Investigators. The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. *American Heart Journal*. 150(5):1086-91, 2005 Nov. PMID:16291003.
133. Anderson DJ. Fangman W. Fowler VG. **Corey GR**. Sexton DJ. A returning traveler with fever and rash. *Clinical Infectious Diseases*. 41(10):1453-4, 1529-30, 2005 Nov 15. PMID:16247837.
134. Chu VH. Crosslin DR. Friedman JY. Reed SD. Cabell CH. Griffiths RI. Masselink LE. Kaye KS. **Corey GR**. Reller LB. Stryjewski ME. Schulman KA. Fowler VG Jr. *Staphylococcus aureus* bacteremia in patients with prosthetic devices: costs and outcomes. *American Journal of Medicine*. 118(12):1416, 2005 Dec. PMID: 16378797.
135. Turner M. **Corey GR**. Abrutyn E. Telithromycin. *Ann Int Med* 2006 Mar 21;144(6):447-8. PMID:16549859.

136. Stryjewski ME. Chu VH. O'Riordan WD. Warren BL. Dunbar LM. Young DM. Vallee M. Fowler VG Jr. Morganroth J. Barriere SL. Kitt MM. **Corey GR.** FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. *Antimicrob Agents Chemother* 2006 Mar;50(3):862-7. PMID:16495243.
137. Inrig JK. Reed SD. Szczech LA. Engemann JJ. Friedman JY. **Corey GR.** Schulman KA. Reller LB. Fowler VG Jr. Relationship between clinical outcomes and vascular access type among hemodialysis patients with *Staphylococcus aureus* bacteremia. *Clinical Journal of The American Society of Nephrology: CJASN.* 2006 May;1(3):518-24May. PMID:17699254.
138. Kourany WM. Miro JM. Moreno A. **Corey GR.** Pappas PA. Abrutyn E. Hoen B. Habib G. Fowler VG Jr. Sexton DJ. Olaison L. Cabell CH. ICE MD Investigators. Influence of diabetes mellitus on the clinical manifestations and prognosis of infective endocarditis: a report from the International Collaboration on Endocarditis-Merged Database. *Scandinavian Journal of Infectious Diseases* 2006; 38(8):613-9. PMID:16857604.
139. Weems JJ Jr. Steinberg JP. Filler S. Baddley JW. **Corey GR.** Sampathkumar P. Winston L. John JF. Kubin CJ. Talwani R. Moore T. Patti JM. Hetherington S. Texter M. Wenzel E. Kelley VA. Fowler VG Jr. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of *Staphylococcus aureus* bacteremia. [Clinical Trial, Phase II. Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial. Research Support, Non-U.S. Gov't] *Antimicrob Agents Chemother.* 2006 Aug; 50(8):2751-5. PMID:16870768.
140. Lalani T. Kanafani ZA. Chu VH. Moore L. **Corey GR.** Pappas P. Woods CW. Cabell CH. Hoen B. Selton-Suty C. Doco-Lecompte T. Chirouze C. Raoult D. Miro JM. Mestres CA. Olaison L. Eykyn S. Abrutyn E. Fowler VG Jr. The International Collaboration on Endocarditis Merged Database Study Group. Prosthetic valve endocarditis due to coagulase-negative staphylococci: findings from the International Collaboration on Endocarditis Merged Database. *Eur Journal of Clin Microbiol Inf Dis* 2006 Jun; 25(6):365-8. PMID:16767483.
141. Fowler VG Jr. Boucher HW. **Corey GR.** Abrutyn E. Karchmer AW. Rupp ME. Levine DP. Chambers HF. Tally FP. Vigliani GA. Cabell CH. Link AS. DeMeyer I. Filler SG. Zervos M. Cook P. Parsonnet J. Bernstein JM. Price CS. Forrest GN. Fatkenheuer G. Gareca M. Rehm SJ. Brodt HR. Tice A. Cosgrove SE. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N Eng J Med* 2006 Aug 17; 355(7):653-65. PMID:16914701.
142. Anguera I, Miro J., San Roman J., de Alarcon A., anguita M., Almirante B., Evangelista A., Cabell C., Vialcosta., Ripoll T., Munoz P., Navas E., Gonzales-Juanatey C., Garcia-Bolao I., Farinas M., Rufi G., Pare C., Fowler V., Mestres C., de Lazzari E., Guma J., del Rio A., **Corey GR.** Periannular complications in infective endocarditis involving prosthetic aortic valves. *American Journal of Cardiology* 2006 Nov 1;98(9)1261-8. PMID:17056342.

143. Anguera I. Miro JM. Evangelista A. Cabell CH. San Roman JA. Vilacosta I. Almirante B. Ripoll T. Farinas MC. Anguita M. Navas E. Gonzalez-Juanatey C. Garcia-Bolao I. Munoz P. de Alarcon A. Sarria C. Rufi G. Miralles F. Pare C. Fowler VG Jr. Mestres CA. de Lazzari E. Guma JR. Moreno A. **Corey GR.** Aorto-Cavitary Fistula in Endocarditis Working Group. Periannular complications in infective endocarditis involving native aortic valves. *American Journal of Cardiology* 2006 Nov 1; 98(9):1254-60. PMID:17056343.
144. Stryjewski ME. Szczech LA. Benjamin DK Jr. Inrig JK. Kanafani ZA. Engemann JJ. Chu VH. Joyce MJ. Reller LB. **Corey GR.** Fowler VG Jr. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible *Staphylococcus aureus* bacteremia. *Clin Inf Dis* 2007 Jan 15;44(2):190-6. PMID:17173215.
145. Aksoy O., Sexton D., Wang A., Pappas P. Kourany W., Chu V., Fowler V., Woods C., Engemann J., **Corey GR.**, Harding T., Cabell C. Early surgery in patients with infective endocarditis: a propensity score analysis. *Clin Inf Dis.* 2007 Feb 1;44(3):364-72. PMID:17205442.
146. Yongsunthon R. Fowler VG Jr. Lower BH. Vellano FP 3rd. Alexander E. Reller LB. **Corey GR.** Lower SK. Correlation between fundamental binding forces and clinical prognosis of *Staphylococcus aureus* infections of medical implants. *Langmuir* 2007 Feb 27; 23(5):2289-92. PMID:17274638.
147. Sexton DJ., McDonlad M., Spelman D., Stryjewski M., Yung A., **Corey GR.** Thirty Operating Rules for Infectious Diseases Apprentices. *Infectious Diseases in Clinical Practice.* 2007 March; 15 (2).
148. Wang A., Athan E., Pappas P., Fowler V., Olaison L., Pare C., Almirante B., Munoz P., Rizzi M., Naber C., Logar M., Tattevin P., Iarussi D., Seton-Suty C., Jones S., Casabe J., Morris A., **Corey GR.**, Cabell CH. International Collaboration on Endocarditis-Prospective Cohort Study Investigators. Contemporary clinical profile and outcome of prosthetic valve endocarditis. *JAMA* 2007 Mar 28;297(12):1354-61. PMID:17392239.
149. Abrutyn E, Cabell CH, Fowler VG, Hoen B, Miro JM, Mestres CA, Sexton DJ, **Corey GR.** Medical treatment of Endocarditis. *Curr Infect Dis Rep.* 2007; 9(4):271-82. PMID:17618546.
150. Kanafani ZA. **Corey GR.** Daptomycin: a rapidly bactericidal lipopeptide for the treatment of gram-positive infections. *Expert Review of Anti-infective Therapy:* 2007 April 5(2):177-84. PMID:17402833.
151. Fowler VG Jr. Nelson CL. McIntyre LM. Kreiswirth BN. Monk A. Archer GL. Federspiel J. Naidich S. Remortel B. Rude T. Brown P. Reller LB. **Corey GR.** Gill SR. Potential associations between hematogenous complications and bacterial genotype in *Staphylococcus aureus* infection. *Journal of Infectious Diseases.* 2007 Sept 1; 196(5):738-47. PMID:17674317.



152. Stryjewski ME. Hall RP. Chu VH. Kanafani ZA. O'Riordan WD. Weinstock MS. Stienecker RS. Streilein R. Dorschner RA. Fowler VG Jr. **Corey GR**. Gallo RL. Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis. *Journal of Infectious Diseases*: 2007 Nov 1;196(9):1425-30. PMID:17922409.
153. Morpeth S. Murdoch D. Cabell CH. Karchmer AW. Pappas P. Levine D. Nacinovich F. Tattevin P. Fernandez-Hidalgo N. Dickerman S. Bouza E. del Rio A. Lejko-Zupanc T. de Oliveira Ramos A. Iarussi D. Klein J. Chirouze C. Bedimo R. **Corey GR**. Fowler VG Jr. International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) Investigators. Non-HACEK gram-negative bacillus endocarditis. *Annals of Internal Medicine*. 2007 Dec 18; 147(12):829-35. PMID:18087053.
154. Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas PA, Federspiel J, Athan E, Stryjewski ME, Nacinovich F, Marco F, Levine DP, Elliott TS, Fortes CQ, Tornos P, Gordon DL, Utili R, Delahaye F, **GR Corey**, Fowler VG, Jr., for the ICE-PCS Study Group. Emergence of Coagulase Negative Staphylococcal Native Valve Endocarditis. *Clin Infect Dis* 2008 Jan 15; 46: 232-242. PMID:18171255.
155. Lalani T. Boucher HW. Cosgrove SE. Fowler VG. Kanafani ZA. Vighiani GA. Champion M. Abrutyn E. Levine DP. Price CS. Rehm SJ. **Corey GR**. Karchmer AW; S. aureus Endocarditis and Bacteremia Study Group. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteremia. *Journal of Antimicrobial Chemotherapy*. 2008 Jan; 61(1):177-82. PMID:17999973.
156. Crowley AL, Peterson GE, Benjamin DK, Rimmer SH, Todd C, Cabell CH, Reller LB, Ryan T, **Corey GR**, Fowler VG Jr. Venous thrombosis in patients with short-and long-term central venous catheter-associated Staphylococcus aureus bacteremia. *Crit Care Med* 2008 Feb; 36(2):385-90. PMID:18091541.
157. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski SE Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, **Corey GR**, and Fowler VG, Jr. Genotypic Characteristics of *Staphylococcus aureus* Isolates from a Multinational Trial of Complicated Skin and Skin Structure Infections. *J. Clin. Microbiol.* 2008 Feb; 46:678-684. PMID:18077636.
158. Caram LB. Linefsky JP. Read KM. Murdoch DR. Lalani T. Woods CW. Reller LB. Kanj SS. Premru MM. Ryan S. Al-Hegelan M. Donnio PY. Orezzi C. Paiva MG. Tribouilloy C. Watkin R. Harris O. Eisen DP, **Corey GR**. Cabell CH. Petti CA. International Collaboration on Endocarditis Investigator Group. Leptotrichia endocarditis: report of two cases from the International Collaboration on Endocarditis (ICE) database and review of previous cases. *Eur J Clin Microbiol Inf Dis*. 2008 Feb; 27(2):139-43. PMID:17960435.
159. Kong MH. **Corey GR**. Bashore T. Harrison JK. Clinical problem-solving. A key miscommunication-n 81-year-old woman presented to the emergency department with increasing

abdominal distention, nausea, and vomiting. *New England Journal of Medicine*. 2008 March 6;358(10):1054-9. PMID:18322287.

- 160.** Liao L, Kong DF, Samad Z, Pappas PA, Jollis JG, Lin SS, Wang A, Fowler VG Jr, Chu VH, Sexton DJ, **Corey GR**, Cabell CH. Echocardiographic risk stratification for early surgery with endocarditis: a cost-effectiveness analysis. *Heart* 2008 May;94(5):e18. PMID:17575328.
- 161.** Boucher HW; **Corey GR**. Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clinical Infectious Diseases*. 46 Suppl 5:S344-9, 2008 Jun 1. PMID:18462089.
- 162.** Stryjewski, M., Graham, D., Wilson, S., O’Riordan, W., Young, D., Lentnek, A., Ross, D., Fowler, V., Hopkins, A., Friedland, D., Barriere, S., Kitt, M., **Corey, R**. Telavancin Versus Vancomycin for the Treatment of Complicated Gram-positive Skin and Skin Structure Infections (ATLAS study). *CID* 2008; 46(1 June) 1683-93. PMID:18444791.
- 163.** Lalani T, Federspiel JJ, Boucher HW, Rude TH, Bae IG, Rybak MJ, Tonthat GT, **Corey GR**, Stryjewski ME, Sakoulas G, Chu VH, Alder J, Steenbergen JN, Luperchio SA, Champion M, Woods CW, Fowler VG. Associations between the genotypes of *Staphylococcus aureus* bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. *J Clin Microbiol*. 2008 Sep; 46 (9):2890-6. Epub 2008 Jul 2. PMID:18596141.
- 164.** Baddley JW, Benjamin DK Jr, Patel M, Miró J, Athan E, Barsic B, Bouza E, Clara L, Elliott T, Kanafani Z, Klein J, Lerakis S, Levine D, Spelman D, Rubinstein E, Tornos P, Morris AJ, Pappas P, Fowler VG Jr, Chu VH, Cabell C; The International Collaboration on Endocarditis—Prospective Cohort Study Group (ICE-PCS). *Candida* infective endocarditis. *Eur J Clin Microbiol Infect Dis*. 2008 Jul ;27 (7): 519-29. PMID :18283504.
- 165.** **Corey GR**, Lalani T. Risk of intravascular cardiac device infections in patients with bacteremia: impact on device removal. *Int J Antimicrob Agents*. 2008 Nov;32 Suppl 1:S26-9. Epub 2008 Sep 5. PMID:18774267.
- 166.** Durante-Mangoni E, Bradley S, Selton-Suty C, Tripodi MF, Barsic B, Bouza E, Cabell C, Ramos A, Fowler V, Hoen B, Konecny P, Moreno A, Murdoch D, Pappas P, Sexton D, Spelman D, Tattevin P, Miró J, van der Meer J, Utili R for the International Collaboration on Endocarditis Prospective Cohort Study Group. Current Features of Infective Endocarditis in the Elderly: Results of the International Collaboration on Endocarditis: Prospective Cohort Study Group. *Arch Intern Med*. 2008 Oct 27;168(19):2095-103. PMID:18955638.
- 167.** Rehm, Susan; Boucher, Helen; Levine, DP; Champion, Marilyn; Eisenstein, Barry; Vigliani, Gloria; **Corey, G**; Abrutyn, Elias. Daptomycin versus vancomycin plus gentamicin for treatment of bacteremia and endocarditis due to *Staphylococcus aureus*: subset analysis of patients infected with

methicillin-resistant isolates. *J Antimicro Chemother.* 2008 Dec;62(6):1413-21. PMID:18782781.

- 168.** Chu VH, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, Stryjewski ME, Anguerra I, Braun S, Munoz P, Commerford P, Tornos P, Francis J, Oyonarte M, Selton-Suty C, Morris AJ, Habib G, Almirante B, Sexton DJ, **Corey GR**, Fowler VG Jr; International Collaboration on Endocarditis. Prospective Cohort Study Group. Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study. *Heart.* 2009 Apr;95(7): 570-6. PMID:18952633.
- 169.** Zeina A. Kanafani, MD, MS<sup>1</sup> and **G. Ralph Corey**, MD. Ceftriaxone: A Cephalosporin with expanded Gram-Positive activity. *Future Microbiol.* 2009 Feb;4:25-33. PMID:19207079.
- 170.** Kanafani Z, Arduino JM, Muhlbaier L, Kaye K, Allen K, Carmeli Y, **Corey GR**, Cosgrove S, Fraser T, Harris A, Karchmer A, Lautenbach E, Rupp M, Peterson E, Straus W, Fowler V. Incidence of and Preoperative Risk Factors for *Staphylococcus aureus* Bacteremia and Chest wound Infection after Cardiac Surgery. *Infect Control Hosp Epidemiol* 2009 Mar; 30:242-248. PMID:19199534.
- 171.** Sara E. Cosgrove, GA Vigliani, M Campion, VG Fowler, E Abrutyn, **Corey GR**, DP Levine, ME Rupp, HF Chambers, AW Karchmer, HW Boucher. Initial Low-dose Gentamicin for *S. aureus* Bacteremia and Endocarditis Is Nephrotoxic. *Clin Infect Dis.* 2009 Mar 15; 48(6):713-21. PMID:19207079.
- 172.** **Corey GR**, Stryjewski, ME, Everts, RJ. Short-course therapy for bloodstream infections in immunocompetent adults. *Int J Antimicro Agents* 2009; 34 (Suppl): S44-48. PMID :19931818.
- 173.** Stryjewski M, Kanafani Z, Chu V, Pappas P, Harding T, Drew L, Benjamin D, Reller B, Benjamin L, **Corey GR**, Fowler V. *Staphylococcus Aureus* Bacteremia among patients with health care-associated fever. *American Journal of Medicine* (2009) 122, 281-289. PMID:19272489.
- 174.** Murdoch DR, **Corey GR**, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21<sup>st</sup> Century. *Arch Intern Med.* 2009 Mar 9;169(5):463-73. PMID:19273776.
- 175.** Eisen DP, **Corey GR**, McBryde ES, Fowler VG Jr, Miro JM, Cabell CH, Street AC, Paiva MG, Ionac A, Tan RS, Tribouilloy C, Pachirat O, Jones SB, Chipigina N, Naber C, Pan A, Ravasio V, Gattringer R, Chu VH, Bayer AS; ICE Investigators. Reduced Valve Replacement surgery and complication rate in *staphylococcus aureus* endocarditis patients receiving acetyl-salicylic acid. *J*

Infect. 2009 May;58(5):332-8. Epub 2009 Mar 20. PMID:19342103.

176. Nannini E, Stryjewski M, and **Corey GR**. Priority Paper Evaluation on: Lunde, C. S., S. R. Hartouni, J. W. Janc, M. Mammen, P. P. Humphrey, and B. M. Benton. 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. *Antimicrob Agents Chemother* May 2009; 53:3375-83.
177. **Corey GR**. *Staphylococcus aureus* Bloodstream Infections: Definitions and Treatment. *CID* 2009 May 15; 48 (Suppl 4): S254-9. PMID:19374581.
178. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, Gould IM, Herrmann M, Hoen B, Karchmer AW, Kobayashi Y, Kozlov RS, Lew D, Miró JM, Moellering RC Jr, Moreillon P, Peters G, Rubinstein E, Seifert H, **Corey GR**. Clinical Consensus Conference: survey on Gram-Positive Bloodstream Infections with a focus on *staphylococcus aureus*. *Clin Infect Dis*. 2009, May 15; 48 Suppl 4:S260-70. PMID:19374582.
179. Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr; ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) Investigators. Health Care-associated Native Valve Endocarditis in Patients with no History of injection drug use: Current Importance of Non-Nosocomial Acquisition. *Ann Intern Med*. 2009 May 5;150(9):586-94. PMID:19414837.
180. Cosgrove SE, **Corey GR**. A balancing act: microbe versus muscle. *Clin Inf Dis*. 2009 Jul 15;49(2):181-3. PMID:19500038.
181. Nannini E, Stryjewski M, Singh KV, Bourgoigne A, Rude T, **Corey GR**, Fowler VG, and Murray BE. Inoculum Effect with Cefazolin among Clinical Isolates of Methicillin-Susceptible *Staphylococcus aureus*: Frequency and Possible Cause of Cefazolin Treatment Failure. *Ant Agents Chemo* 2009 Aug;53(8). 3437-3441. PMID:19487449.
182. Goswami ND, Shah JJ, **Corey GR**, Stout JE. Persistent eosinophilia and Strongyloides infection in Montagnard refugees after presumptive albendazole therapy. *Am J Trop Med Hyg*. 2009 Aug; 81(2):302-4. 19635888.
183. Stryjewski, ME and **Corey GR**. New Treatments for Methicillin-Resistant *Staphylococcus aureus*. *Curr Opin Critical Care* 2009 Oct; 15(5): 403-12. PMID:19561492.
184. Bae I, Tonthat G, Stryjewski M, Rude T, Reilly L, Barriere SL, Genter F, **Corey GR**, Fowler VG Jr. Presence of Genes Encoding the Pantone-Valentine Leukocidin Exotoxin is Not the Primary Determinant of Outcome in Patients with Complicated Skin and Skin Structure Infections due to Methicillin-Resistant *Staphylococcus aureus*: Results of a Multinational Trial. *J Clin Microbiol* 2009 Oct 21 (Epub ahead of print).

- 185.** Tripodi MF, Vigo D, Durante-Mangoni E, Lifschitz A, **Corey GR**, Stryjewski ME, Utili R, Pryluka D: International Collaboration on Endocarditis Prospective Cohort Study. *Rhodococcus equi* endocarditis in immunocompetent hosts: report of the first two cases. *Int J Antimicrob Agents*. 2009 Nov; 34 (5): 496-7. PMID:19589660.
- 186.** Bae I, Federspiel J, Miro J, Woods CW, Park L, Rybak M, Rude TH, Bradley S, Bukovski S, Garcia de la Maria C, Kanj S, Korman T, Marco F, Murdoch D, Plesiat P, Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton K, **Corey GR**, Fowler VG, and International Collaboration on Endocarditis-Microbiology Investigators. Heterogeneous Vancomycin-Intermediate Susceptibility Phenotype in Bloodstream Methicillin-Resistant *S. aureus* Isolates from the International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype and Clinical Significance. *J Inf Dis*: Nov. 2009. Nov 1; 200 (9): 1355-66. PMID:19811099.
- 187.** **Corey GR**. Epidemiology of complicated drug-resistant infections: an overview. *Inf Dis Clin N Am*. 2009 Nov; 34(5) 496-7.
- 188.** **Corey GR**. Stryjewski ME. Weyenberg W. Yasothan U. Kirkpatrick P. Telavancin. *Nature Reviews, Drug Discovery*. 8(12):929-30, 2009 Dec. PMID:19949399.
- 189.** Bae IG. Tonthat GT. Stryjewski ME. Rude TH. Reilly LF. Barriere SL. Genter FC. **Corey GR**. Fowler VG Jr. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant *Staphylococcus aureus*: results of a multinational trial. *Journal of Clinical Microbiology*. 47(12):3952-7, 2009 Dec. PMID:19846653.
- 190.** **Corey GR**. Stryjewski ME. Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. *International Journal of Antimicrobial Agents*. 34 Suppl 4:S47-51, 2009. PMID:19931818.
- 191.** Kanafani ZA. Kourany WM. Fowler VG Jr. Levine DP. Vigliani GA. Champion M. Katz DE. **Corey GR**. Boucher HW. Clinical characteristics and outcomes of diabetic patients with *Staphylococcus aureus* bacteremia and endocarditis. *European Journal of Clinical Microbiology & Infectious Diseases*. 28(12):1477-82, 2009 Dec. PMID:19730900.
- 192.** Lalani T. Cabell CH. Benjamin DK. Lasca O. Naber C. Fowler VG Jr. **Corey GR**. Chu VH. Fenely M. Pachirat O. Tan RS. Watkin R. Ionac A. Moreno A. Mestres CA. Casabe J. Chipigina N. Eisen DP. Spelman D. Delahaye F. Peterson G. Olaison L. Wang A. International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. *Circulation*. 121(8):1005-13, 2010 Mar 2. PMID:20159831.
- 193.** Kanafani Z, Boucher H, Fowler V, Cabell C, Hoen B, Miro J, Lalani T, Viglianai G, Champion M,

- Corey R**, Levine D. Daptomycin compared to standard therapy for the treatment of native valve endocarditis. *Microbiol Clin*. 2010 Feb 24: Epub ahead of print.
- 194.** Nannini EC, Stryjewski M, **Corey GR**. Televancin interactions with the bacterial cell membrane. *Future Microbiol*. 2010 Mar 5 (3): 355-8. PMID:20210546.
- 195.** Nannini EC, Stryjewski M, Singh KV, Rude TH, **Corey GR**, Fowler VG Jr, Murray BE. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2010 May; 54(5):2206-8. Epub 2010 Mar 8. PMID:20211890.
- 196.** Nannini EC, Stryjewski ME, **Corey GR**. Ceftaroline for complicated skin and skin-structure infections. *Expert Opin Pharmacother*. 2010 May; 11(7):1197-1206. PMID:20402556.
- 197.** **Corey GR**, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double-blinded Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin-Structure Infection. *CID* 2010 Aug 9. PMID:206955801.
- 198.** Bennett-Guerrero E, Ferguson TB, Lin M, Garg J, Mark D, Scavo V, Kouchoukos N, Richardson JB, Pridgen RL, **Corey GR** for the Swipe-1 Trial Group. Effect of an Implantable Gentamicin-Collagen Sponge on Sternal Wound Infections Following Cardiac Surgery: A Randomized Trial. *JAMA*, Aug 18, 2010; Vol 304, No 7, page 755-762. PMID:20716738.
- 199.** Bennett-Guerrero E, Pappas T, Koulton W, Fleshman J, Lin M, Garg J, Mark D, Marcet J, Remzi F, George V, Newland K and **Corey GR**, for the Swipe-2 Trial Group. Gentamicin-Collagen Sponge for Infection Prophylaxis in Colorectal Surgery. *New England Journal of Medicine*. 363(11):1038-49, 2010 Sep 9. PMID:20825316.
- 200.** **Corey GR**, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. *Clin Infect Dis*. 2010 Sep 15;51(6):641-50. 20695801.
- 201.** **Corey GR**, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. Canvas 1: the first phase 3, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections *J Antimicrobial Chemother*, 2010 Nov;65 Suppl 4:iv441-51. PMID:21115454.
- 202.** Wilcox MH, **Corey GR**, Talbot GH, Thye D, Friedland D, Baculik T. Canvas 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. *J Antimicrob Chemother*, 2010 Nov;65, Suppl 4. PMID:21115455.

203. Rubinstein E, Lalani T, **Corey GR**, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; ATTAIN Study Group. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. *Clin Infect Dis*. 2011 Jan;52(1):31-40. PMID:21148517.
204. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB and **Corey GR**. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. *Antimicrobial Agents and Chemotherapy*. 55(2):583-92, 2011 Feb. PMID:21115795.
205. Hannan MM, Husain S, Mattner F, Danzinger-Isakov L., **Corey GR**, Schueler S, Holman WL, Lawler LP, Gordon SM, Mahon NG, Herre JM, Gould K, Montoya JG, PAdera RF, Kormos RL, Conte JV, Mooney ML. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. *Journal of Heart & Lung Transplantation*. 30(4):375-84, 2011 April. PMID:21419995.
206. Thornhill MH, Dayer MJ, Forde JM, **Corey GR**, Chu VH, Couper DJ, Lockhart PB. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. *BMJ*. 2001 May 3;342:d2392.
207. Bloomfield GS. Kimaiyo S. Carter EJ. Binanay C. **Corey GR**. Einterz RM. Tierney WM. Velazquez EJ. Chronic noncommunicable cardiovascular and pulmonary disease in sub-Saharan Africa: an academic model for countering the epidemic. [Review] *American Heart Journal*, 161(5): 842-7, 2011 May. PMID:21570512.
208. Craft JC. Moriarty SR. Clark K. Scott D. Degenhardt TP. Still JG. **Corey GR**. Das A. Fernandes P. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. *Clinical Infectious Disease*. 52, Suppl 7:S520-6, 2011 June. PMID:21546629.
209. **Corey, GR**, Stryjewski M. New rules for clinical trials of patients with acute bacterial skin and skin structure infections: do not let the perfect be the enemy of the good. *CID Suppl 7*:S469-76, 2011 June. PMID:21546623.
210. Moellering RC, **Corey GR**, Grayson ML. Introduction: fusidic acid enters the United States. *CID 52 Suppl 7*:S467-8, 2011 June. PMID:21546622.
211. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamletthson S, Park L, Rude TH, Barriere S, Woods CW, Chu VH, Marín M, Bukovski S, Garcia P, **Corey GR**, Korman T, Doco-Lecompte T, Murdoch DR, Reller LB, Fowler VG Jr; International Collaboration on Endocarditis-Microbiology Investigators. Methicillin-susceptible *Staphylococcus aureus* endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. *J Infect Dis*. 2011

Sep 1;204(5):704-13. PMID:21844296.

212. Chow SC, **Corey GR**. Benefits, challenges and obstacles of adaptive clinical trial design. *Orphanet J Rare Dis*. 2011 Nov 30;6:79. PMID: 22405401.
213. Rubinstein E, **Corey GR**, Stryjewski M, Kanfani Z. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. *Expert Opin Pharmacother*. 2011 Dec;12(17):2730-50. Review. PMID: 22077833.
214. Rangwala F, Putcharoen O, Bowonwatanuwong C, Edwards-Jackson N, Kramomthong S, Kim JH, **Corey GR**, Ananworanich J. Histoplasmosis and penicilliosis among HIV-infected Thai patients: a retrospective review. *Southeast Asian J Trop Med Public Health*. 2012 Mar;43(2):436-41. PMID:23082594.
215. Kanafani, Z. and **Corey GR**. Tedezolid (TR-701): a new oxazolidinone with enhanced potency. *Expert Opinion on Investigational Drugs*. April 2012. Volume 21. Pages 515-522. PMID:22324973.
216. Athan E, Chu VH, Tattevin P, Selton-Suty C, Jonas P, Naber C, Miro JM, Ninot S, Fernandez\_hidalgo N, Durante-Mangoni E, Spelman D, Hoen B, Lejko-Zupanc T, Cecchi E, Thuny F, Hannan MM, Pappas P, Henry M, Fowler VG, Crowley AL, Wang A, ICE\_PCS Investigators. Clinical Characteristics and outcome of infective endocarditis involving implantable cardiac devices. *JAMA* 2012 April 25;307(16);1727-35. PMID:22535857.
217. Chen LF, Arduino JM, Sheng S, Muhlbaier LH, Kanafani ZA, Harris AD, Fraser TG, Allen K, **Corey GR**, Fowler VG Jr. Epidemiology and outcome of major postoperative infections following cardiac surgery: Risk factors and impact of pathogen type. *Am J Infect Control*. 2012 May 19. PMID:22609237.
218. Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, **Corey GR**. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. *J Antimicrob Chemother*. 2012 Jun;67(6):1496-502. PMID:22416054
219. Chow SC, **Corey GR**, and Lin M. On the independence of data monitoring committee in adaptive design clinical trials. *Journal of Biopharm Stat*. 2012;22(4):853-67. PMID: 22651119.
220. Nannini, E, **Corey GR**, Stryjewski ME. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies. *Expert Review Anti Infect Ther*. 2012 August;10(8):847-54. PMID: 23030322
221. **Corey GR**, Jones RN. Ceftaroline applications for therapy in the United States. *CID* 2012 Sept;55 Suppl 3:S171-2. PMID: 22903948.
222. Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, **Corey GR**; for the TD-1792 Investigators Group. TD-1792 versus Vancomycin for Treatment of Complicated Skin and



Skin Structure Infections. *Antimicrobial Agents Chemother.* 2012 Nov;56(11):5476-5483. PMID: 22869571.

223. Chirouze C, Athan E, Alla F, Chu VH, **Corey GR**, Selton-Suty C, Erpelding ML, Miro JM, Olaison L, Hoen B; the International Collaboration on Endocarditis Study Group. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Pro prospective Cohort Study. *Clin Microbiol Infect.* 2013 Feb 7. doi: 10.1111/1469-0691.12166. PMID: 23517406
224. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, **Corey GR**, Carmeli Y, Betts R, Hartzel JS, Chan ISF, McNeely TB, Karsonis NA, Guris D, Onorato MT, Smuger SS, DiNubile MJ, Sobanjo-ter Meulen A. Effect of an investigational vaccine for preventing *Staphylococcus aureus* infections after cardiothoracic surgery. *JAMA.* 2013;309(13):1368-1378. doi: 10.1001/jama.2013.3010. PMID: 2354958
225. Lalani T, Chu, VH, Park LP, Cecchi E, **Corey G**, Durante-Mangoni E, Fowler VG, Gordon D, Grossi P, Hannan M, Hoen B, Munoz P, Rizk H, Kanj SS, Selton-Suty C, Sexton DJ, Spelman D, Ravasio V, Tripodi MF, Wang A for the International Collaboration on Endocarditis-Pro prospective. In-hospital and one year mortality in patients undergoing early surgery for prosthetic valve endocarditis. *JAMA Intern Med.* 2013;173(16):1495-504. doi:10.1001/jamainternmed.2013.8203. Erratum in: *JAMA Intern Med.* 2013 Oct 28;173(19):1846. PMID: 23857547.
226. Chambers S, Murdoch D, Morris A, Holland D, Pappas P, Almela M, Fernandez-Hidalgo N, Almirante B, Bousa E, Forno D, del Rio A, Hannan M, Harkness J, Kanafani Z, Lalani T, Land S, Raymond N, Read K, Vinogradova T, Woods C, Wray D, **Corey R**, Chu V. HACEK Infective endocarditis: characteristics and outcomes from a large, multi-national cohort. *PLOS ONE* 8(5): e63181. Doi:10.1371/journal.pone.0063181. PMID: 23690995.
227. Langley R, Tsalik E, van Velkinburg J, Glickman S, Rice B, Wang C, Chen B, Carin L, Suarez A, Mohny RP, Freeman DH, Oien NC, Wang M, You J, Wulff J, Thompson JW, Mosely MA, Reisinger S, Edmonds BT, Grinnell B, Nelson DR, Dinwiddle DL, Miller NA, Saunders CJ, Soden SS, Rogers AJ, Gazourian L, Freeddenburgh L, Massaro AF, Baron RM, Choi AMK, **Corey GR**, Ginsburg GS, Cairns CB, Otero RM, Fowler VG, Rivers EP, Woods CW, Kingsmore SF. An integrated clinico-metabolomic model improves prediction of death in sepsis. *Science Translational Medicine.* 2013;5(195):195ra95. doi: 10.1126/scitranslmed.3005893. PMID: 23884467.
228. Stryjewski, M; Barriere, S; Rubinstein, E; Genter, F; Lentnek, A; Magana-Aquino, M; Luna, C; Neiderman, M; Torres, A, **Corey, GR**. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. *Int J Antimicrob Agents.* 2013. Oct; 42(4):369-369. doi: 10.1016/j.ijantimicag.2013.06.003. PMID: 23891527.
229. Catania J, Martin SS, **Corey GR**, Sexton DS. Diagnostic dilemma in a returning traveler with fever. *Diagn Microbiol Infect Dis.* 2013. 77:85-86. doi: 10.1016/j.diagmicrobio.2013.05.013. PMID: 23871414.

230. Carugati M, Bayer A, Miro J, Park L, Guimaraes A, Skoutelis A, Fortes C, Durante-Mangoni E, Hannan M, Nacinovich F, Fernandez-Hidalgo N, Grossi P, Tan R, Holland T, Fowler V, **Corey GR** and Chu V. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis (ICE). *Antimicrobial Agents and Chemotherapy*. 2013 Dec;57(12):6213-22. doi: 10.1128/AAC.01563-13. Epub 2013 Sep 30. PMID:24080644
231. Stryjewski ME, **Corey GR**. Methicillin-resistant *staphylococcus aureus*: an evolving pathogen. *Clinical Infectious Diseases*. CID 2014;58 (Suppl 1):S10-19. doi: 10.1093/cid/cit613. PMID: 24343827.
232. Torres A, Rubinstein E, **Corey G**, Stryjewski M, Barriere S. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. *J Antimicrob Chemotherapy*. Apr;69(4):1119-26. Published online 1/6/14 doi: 10.1093/jac/dkt490. PMID: 24398339.
233. Barriere SL, Stryjewski ME, **Corey GR**, Genter FD, Rubinstein E. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to *Staphylococcus aureus*: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies. *BMC Infect Dis* 2014. 14:183. doi: 10.1186/1471-2334-14-183. PMID: 24708675. PMCID: PMC4101862
234. Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG Jr, Barriere SL, Kitt MM, **Corey GR**. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated *Staphylococcus aureus* bacteremia: the ASSURE study. *BMC Infect Dis*. 2014 May 23;14:289. doi: 10.1186/1471-2334-14-289. PMID: 24884578.
235. **Corey GR**, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W; SOLO I Investigators. *N Engl J Med*. 2014 Jun 5;370(23):2180-90. Doi: 10.1056/NEJMoa1310422. PMID: 24897083.
236. **Corey GR**, Kollef MH, Shorr AH, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL. Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. *Antimicrob Agents Chemother*. 2014 Jun;58(4):2030-7. Doi: 10.1128/AAC.02330-13. [Epub 2014 Jan 13. Erratum in *Antimicrob Agents Chemother*. 2014 June;58(6):3581 . PMID: 24419353.
237. Moran GJ, Fang E, **Corey GR**, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis*. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5. PMID: 24909499.
238. **Corey GR**, Jiang H, Moeck G. Dalbavancin or oritavancin for skin infections. *N Engl J Med*. 2014 Sep 18;371(12):1162-3. PMID: 25243251.
239. Tsalik EL, Langley RJ, Dinwiddie DL, Miller NA, Yoo B, van Velkinburgh JC, Smith LD, Thiffault I, Jaehne AK, Valente AM, Henao R, Yuan X, Glockman SW, Rice BJ, McClain MT, Carin L, **Corey**

- GR**, Ginsburg GS, Cairns CB, Otero RM, Fowler VG Jr, Rivers EP, Woods CW, Kingsmore SF. An integrated transcriptome and expressed variant analysis of sepsis survival and death. *Genome Med.* 2014 Nov 26;6(11):111. Doi: 10.1186/s13073-014-0111-5. eCollection 2014. PMID: 25538794.
- 240.** **Corey GR**, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O’Riordan W for SOLO II Investigators. Single-dose Oritavancin compared to 7-10 days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: the SOLO II Non-inferiority study. *Clin Inf Dis.* 2015 Jan 15; 60(2):254-62. Doi: 10.1093/cid/ciu778 PMID: 25294250 [Epub ahead of print 2014 Oct 6].
- 241.** Stryjewski ME, **Corey GR**. NOVA score to predict endocarditis in patients with enterococcal bacteremia: sticking to valves or to scores? *Clin Infect Dis.* 2015 Feb 15;60(4):536-8. Doi: 10.1093/cid/ciu878. [Epub ahead of print 2014 Nov 7] PMID: 25381322.
- 242.** Chirouze C, Alla F, Fowler VG Jr, Sexton DJ, **Corey GR**, Chu V, Wang A, Erpelding ML, Durante-Mangoni E, Fernández-Hidalgo N, Giannitsioti E, Hannan MM, Lejko-Zupanc T, Miró JM, Muñoz P, Murdoch DR, Tattevin P, Tribouilloy C, Hoen B; on behalf of the ICE Prospective Investigators. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis - Prospective Cohort Study. *Clin Infect Dis.* 2015 Mar 1;60(5):741-9. Doi: 10.1093/cid/ciu871. [Epub ahead of print 2014 Nov 10] PMID: 25389255.
- 243.** Shorr A, Lodise T, **Corey GR**, DeAnda C, Fang E, Das A, Prokocimer P. Analysis of the Phase 3 ESTABLISH Trials of Tedizolid Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections. *Antimicrob Agents Chemother.* 2015 Feb;59(2):864-71. Doi: 10.1128/AAC.03688-14. [Epub ahead of print 2014 Nov 24]. PMID 25421472.
- 244.** **Corey GR**, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL. Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus. *Clin Inf Dis.* 2015 Mar 1;60(5):787-96. Doi: 10.1093/cid/ciu971. [Epub ahead of print 2014 Dec 3]. PMID: 25472944.
- 245.** Stryjewski ME, Jones RN, **Corey GR**. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. *Diagn Microbiol Inf Dis.* 2015 Mar;81(3):183-8. Doi: 10.1016/j.diagmicrobio.2014.11.016. [Epub ahead of print 2014 Dec 2]. PMID: 25583130.
- 246.** Durkin MJ, **Corey GR**. New developments in the management of severe skin and deep skin structure infections – focus on tedizolid. *Ther Clin Risk Manag.* 2015 May 22;11:857-62. Doi: 10.2147/TCRM.S64553. eCollection 2015. Review. PMID: 26045667.
- 247.** Messina JA, Fowler VA Jr, **Corey GR**. Oritavancin for acute bacterial skin and skin structure infections. *Expert Opin Pharmacother.* 2015 May;16(7):1091-8. Doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24. PMID: 25803197.

248. Thom H, Thompson JC, Scott DA, Halfpenny N, Sulham K, **Corey GR**. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. *Curr Med Res Opin*. 2015 Jun 29;1-13 [Epub ahead of print] PMID: 26038985.
249. Pushkin R, Barriere SL, Wang W, **Corey GR**, Stryjewski ME. Telavancin for acute bacterial skin and skin structure infections (ABSSSI) – A post-hoc analysis of the Phase 3 ATLAS Trials in consideration of the Final (2013) FDA Guidance. *Antimicrob Agents Chemother*. Oct;59(10):6170-4. doi: 10.1128/AAC.00471-15. Epub 2015 Jul 27. PMID: 26248356.
250. Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, **Corey GR**, Barriere SL. Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality. *Clin Infect Dis*. 2015 Sep 15;61 Suppl 2:S87-93. doi: 10.1093/cid/civ536. PMID:26316562
251. Kauf TL, McKinnon P, **Corey GR**, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T. An open-label, pragmatic randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. *BMC Infect Dis*. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9. PMID: 26547411
252. Binanay CA, Akwanalo CO, Aruasa W, Barasa FA, **Corey GR**, Crowe S, Esamai F, Einterz R, Foster MC, Gardner A, Kibosia J, Kimaiyo S, Koech M, Korir B, Lawrence JE, Lukas S, Manji I, Maritim P, Ogaro F, Park P, Pastakia SD, Sugut W, Vedanthan R, Yanoh R, Velazquez EJ, Bloomfield GS. Building sustainable capacity for cardiovascular care at a public hospital in Western Kenya. *J Am Coll Cardiol*. 2015 Dec 8;66(22):2550-60. Doi: 10.1016/j.jacc.2015.09.086. PMID: 26653630.
253. Johnson JA, Feeney ER, Kubiak DW, **Corey GR**. Prolonged use of Oritavancin for Vancomycin-resistant *Enterococcus faecium* prosthetic valve endocarditis. *Open Forum Inf Dis*. 2015 Oct 29;2(4):ofv156. Doi: 10.1093/ofid/ofv156. eCollection 2015 Dec. PMID: 26677455.
254. Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, **Corey GR**, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW. A response adaptive randomization platform trial for efficient evaluation of ebola virus treatments: A model for pandemic response. *Clin Trials*. 2016 Feb;13(1):22-30. Epub 2016 Jan 14. PMID: 26768569. Doi: 10.1177/1740774515621721.
255. Sivak JA, Vora AN, Navar AM, Schulte PJ, Crowley AL, Kisslo J, **Corey GR**, Liao L, Wang A, Velazquez EJ, Samad Z. An approach to improve the negative predictive value and clinical utility of transthoracic echocardiography in suspected native valve infective endocarditis. *J Am Soc Echocardiogr* 2016. Apr;29(4):315-22. Epub 2016 Feb 3. PMID: 26850679. Doi: 10.1016/j.echo.2015.12.009.
256. Bennett-Guerrero E, Minkowitz HS, Segura-Vasi AM, Marcet JE, White JA, **Corey GR**, Allenby KS. A randomized, double-blind, placebo controlled safety, tolerability, and pharmacokinetic dose escalation

study of a gentamicin vancomycin gel in patients undergoing colorectal surgery. *Perioper Med (Lond)*. 2016 Jun 16;5:17. PMID: 27313846. Doi: 10.1186/s13741-016-0043-2.

257. Tarakji KG, Mittal S, Kennergren C, **Corey GR**, Poole J, Stromberg K, Lexcen DR, Wilkoff BL. Worldwide randomized antibiotic envelope Infection Prevention Trial (WRAP-IT). *Am Heart J* 2016; 180:12-21. PMID: 27659878.
258. **Corey GR**, Arhin F, Wikler M, Sahm D, Kreiswirth B, Mediavilla J, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O’Riordan W. Pooled analysis of single dose oritavancin in the treatment of acute bacterial skin and skin structure infections caused by gram-positive pathogens, including a large patient subset with methicillin-resistant staphylococcus aureus. *Int J Antimicrob Agents*. 2016 Nov;48(5):528-534. PMID: 27665522. Doi: 10.1016/j.ijantimicag.2016.07.019.
259. Smart JI, **Corey GR**, Stryjewski ME, Wang W, Barriere SL. Assessment of minimum inhibitory concentrations of Telavancin by revised broth microdilution method in phase 3 hospital-acquired pneumonia/ventilator-associated pneumonia clinical trial isolates. *Inf Dis Ther*. 2016 Dec; 5(4):535-544. PMID 27718118. DOI 10.1007/s40121-016-0133-y.
260. Nathwani D, **Corey R**, Das AF, Sandison T, De Anda C, Prokocimer P. Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials. *Clin Infect Dis*. 2017 Jan 15;64(2):214-217. doi: 10.1093/cid/ciw750. Epub 2016 Dec 21.
261. Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials. *Open Forum Infect Dis*. 2017 Winter; 4(1): ofw274. Published online 2017 Jan 19. doi: 10.1093/ofid/ofw274. PMID: 28480266
262. Bennett-Guerrero E, Berry S, Bergese SD, Fleshner PR, Minkowitz HS, Segura-Vasi AM, Itani KMF, Henderson KW, Rackowski F, Aberle LH, Stryjewski ME, **Corey GR**, Allenby KS. A randomized, blinded, multicenter trial of gentamicin vancomycin gel (DFA-02) in patients undergoing abdominal surgery. *Am J Surg*. 2017 Jun;213(6):1003-1009. Doi: 10.1016/j.amjsurg.2016.10.007 PMID: 27989501.
263. Smart JI, **Corey GR**, Stryjewski ME, Wang W, Barriere SL. Assessment of televancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates. *Diagn Microbiol Infect Dis*. 2017 Mar;87(3):268-271. Doi: 10.1016/j.diagmicrobio.2016.12.009 PMID: 28038840.
264. Doernberg SB, Lodise TP, Thaden JT, Munita JM, Cosgrove SE, Arias CA, Boucher HW, **Corey GR**, Lowy FD, Murray B, Miller LG, Holland TL; Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG). Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. *Clin Infect*

### Articles Submitted or In Preparation:

1. Tong SYC, Park LP, Pappas PA, Lauridsen TK, Krajinovic V, Rodríguez-Créixems M, Korman T, Miró JM, Fernández-Hidalgo N, Signorini L, Delahaye F, Murdoch DR, Rude1 TH, **Corey GR**, Woods CW, Chu VH, Fowler VG, International Collaboration on Endocarditis Investigators. Staphylococcus aureus Infective Endocarditis Survival Differs by Geography. Submitted.
2. **Corey GR**, Moran G, Goering R, Bensaci M, Sandison T, De Anda C, Prokocimer P. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials. Target journal: J Antimicrobial Chemotherapy. Submitted on 11/30/16.
3. Huang DB, File TM, Dryden M, **Corey GR**, Torres A, Wilcox MH. Surveillance of Iclaprim activity: In vitro susceptibility of Gram-positive pathogens collected from 2012-2014 from the United States, Asia Pacific, Latin America and Europe.

### Non-refereed publications:

1. **Corey GR**, Li J. Letter to the Editor. NC Med J, 1997.
2. **Corey GR**, Stryjewski ME. Reply to Solnick. Clin Infect Dis. 2015 Aug 1;61(3):485-6. Doi: 10.1093/cid/civ372. Epub 2015 May 8. PMID: 25956892.
3. Prokocimer P, **Corey GR**, Das AF, Moran GJ. A closer inspection of tedizolid – authors' reply. Lancet Infect Dis. 2015 Apr;15(4):375. Doi: 10.1016/S1473-3099(15)70103-9. PMID: 25809888.
4. **Corey GR**, Boucher HW, Stryjewski ME. Reply to DiNubile. Clin Infect Dis. 2015 Apr 15;60(8):1291-2. Doi: 10.1093/cid/civ025. Epub 2015 Jan 21. PMID: 25609681.

### Chapters in Books

1. **Corey R**, Cohen JI: Septic Shock. In: Medicine & Pediatrics in One Book. Crapo JD, Hamilton, MA, Edgman S (eds). Hanley & Belfus, Philadelphia, pgs 534-536, 1988.
2. **Corey R**, Cohen JI: Fever of Unknown Origin. In: Medicine & Pediatrics in One Book. Crapo JD, Hamilton MA, Edgman S (eds). Hanley & Belfus, Philadelphia, pgs. 537-541, 41988.
3. Li J, **Corey R**: Osteomyelitis. In: Conn's Current Therapy. Rakel RE (ed), WB Saunders Co., pgs. 853-857, 1988.
4. **Corey GR**: Hemoptysis. In: Walker HK, Hall WD, Hurst JW, eds. Clinical Methods. 3rd Edition. Boston, MA. Butterworth 1990: pgs. 211-213.
5. Sexton, DJ and **RC Corey**. Infective endocarditis: Case definitions and criteria for diagnosis. In: *Up To Date*. BD Rose (Ed), BDR Inc, Wellesley MA, Vol. 4. 1996-2002.

6. Nichols G, **Corey GR**. Myocarditis and Pericarditis. In: Infectious Diseases, Mosby 1999; Chapter 49: 1-10.
7. Li J, **Corey GR**. Clinical Approach to Large Pericardial Effusion. In: *Up To Date*. Submitted, 1997-2002.
8. **Corey, R**, Armitage, JO. Venomous Snake Bites. Cecil's Textbook of Medicine. 2003, 2007.
9. Stryjewski, M, **Corey, GR**. Treatment of Infective Endocarditis. John Pace
10. Li, J, **Corey, GR**, Fowler, GR. Infective Endocarditis. Textbook of Cardiovascular Medicine. Eric Topol, 2007.
11. Steven A. Seifert, James O. Armitage and **G. Ralph Corey**. Venomous Snake Bites. Cecil Textbook
12. Martin E. Stryjewski, Esteban C. Nannini & **G. Ralph Corey**: Skin and Soft Tissue Infections. In: Staphylococci in Human Disease. Kent Crossley, Kimberly Jefferson, Gordon Archer, Vance Fowler (eds). Wiley-Blackwell, Pages 378-394, 2009.
13. **Corey, GR**. Myocarditis and Pericarditis. Infectious Diseases, Mosby 2010.
14. Banks, A and **Corey GR**. Myocarditis and Pericarditis. Infectious Diseases, Elsevier 2016.

**Books:**

N/A

**Other:**

**a. Published scientific reviews**

N/A

**b. Selected Abstracts**

1. St. Clair EW, Feussner JR, Waugh RA, Wade LL, DeLong ER, **Corey GR**: Assessing the cardiovascular diagnostic skills of medical residents using a cardiology patient simulator. Southern Section SREPCIM, American Federation for Clinical Research, 1986.
2. Tapson VF, **Corey GR**, Feussner JR, DeLong ER, MacGregor JH, Ravin CE: Comparative accuracy of chest x-ray interpretation at various levels of physician training. Southern Section SREPCIM, American Federation for Clinical Research, 1987.
3. Brown JT, Linzer M, **Corey GR**, McLamb GP: The Duke Primary Care Residency Program: Starting without federal funding and effective use of an orientation module to teach a core curriculum in ambulatory medicine. APDIM, March, 1988.
4. Kenney RT, O'Connor CM, Wall TC, Kraus WE, van Trigt P, Smith P, Pryor D, Kisslo J, **Corey GR**: A prospective trial of subxiphoid pericardiectomy in the diagnosis and treatment of large pericardial effusions. A preliminary report. ACP, March, 1988.
5. Clyde WA, Wall TC, O'Connor CM, Kenney RT, van Trigt P, Hill GB, **Corey GR**: Mycoplasma pneumoniae Pericarditis: Two cases with isolation of the organism from pericardial fluid. 7th Intl. Congress of Intl. Org. for Mycoplasma, Braden near Vienna, Austria. June 2-9, 1988.
6. Campbell PT, Sheikh KH, Kisslo J, O'Connor CM, Wall TM, Smith P, Owens PM, **Corey, GR**: Subxiphoid Pericardiectomy is safe and efficacious in the diagnosis and management of large pericardial effusions. 62nd Scientific American Heart Association, November, 1989.
7. Campbell PT, Wall TC, O'Connor CM, Van Trigt P, Kenney RT, Owens PM, **Corey RG**. Subxiphoid pericardial biopsy and fluid analysis for diagnosis of malignancy or infection in patients with large

- pericardial effusions. *Circulation* 80:II-667, 1989.
8. Campbell TP, Wall T, O'Connor CM, Van Trigt P, Sheikh KH, Kisslo J, **Corey R**. Cardiac Tamponade: clinical features and management by subxiphoid pericardiotomy. *J Am Coll Cardiol* 17:382A, 1991.
  9. Wong JG, **Corey GR**, Brown JT: Teaching topics in primary care: A new outpatient rotation for houseofficer training. *APDIM*, April 1991.
  10. Goel N, and **Corey GR**: Autoimmune Hemolytic Anemia Precipitated by Salmonella Infection. *ACP*, 1991.
  11. Tapson VF, **Corey GR**, Feussner JR, DeLong ER, MacGregor JH, Ravin CE. Comparative Accuracy of Chest X-Ray interpretation at Various Levels of Physician Training. Southern Section SREPCIM, Sept 1991.
  12. Sexton DJ, **Corey GR**, Breitswerdt E, Hegerty B, Muniz M, Dietze R, Dumler S, and Walker DH. Brazilian spotted fever in Espirito Sancto, Brazil: description of a focus of infection in a new endemic region. *Am Soc for Rickettsiology and Rickettsial Diseases*, Tenth Sesqui-Annual Meeting, Rocky Mountain Laboratories, September 17-19, 1992.
  13. Dietze R, Reis JA, Rohr MRS, Teixeira L, Pecanha PH, Falqueto A, Sexton DJ, **Corey GR**: Febre maculosa Brasileira: descricao do primeiro surto da doenga no Espirito Santo OAbstract No. 217). Presented at XXVIII Congresso do Sociedade Brasileira de Medicina Tropical Belem PA, Brazil, February 23-27, 1992.
  14. Sexton DJ, Kanj SS, Wilson K, **Corey GR**, Hegarty BC, Breitschwerdt EF: The use of polymerase chain reaction as a diagnostic test for Rocky Mountains spotted fever. Tenth Sesqui-Annual Meeting of American Society for Rickettsiology and Rickettsial Diseases, Hamilton, Montana, September 16-19, 1992.
  15. Weinstein JW, Roe M, Townes M, Sanders L, Thorpe J, **Corey GR**, Sexton DJ. Resistant enterococci: prevalence, incidence, and factors associated with colonization. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 4-7, 1994.
  16. Dodds GA, Durack DT, **Corey GR**, Kisslo J, Sexton SJ, Duke Endocarditis Service. Validation of New Duke Criteria for the Clinical Diagnosis of Infective Endocarditis: Follow-up of "Rejected" Cases. 67th Scientific American Heart Association, Dallas, TX, November 14-17, 1994.
  17. Abramson MA, Abolnik IZ, Tysmans J, **Corey GR**, Sexton DJ. Medical Risks and Problems Related to International Travel. 33rd Annual Meeting of IDSA, San Francisco, CA, September 16, 1995.
  18. Abramson MA, Abolnik IZ, Tysmans J, **Corey GR**, Sexton DJ. Medical risks and problems related to international travel. 33rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, CA. September 16, 1995.
  19. Abolnik IZ, Cleveland KO, Fahhoum JS, Abramson MA, **Corey GR**, Gelfand MS, Sexton DJ. Nosocomial Fever of Unknown Origin (FUO). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995.
  20. Roe MT, Abramson M, Sexton DJ, Li J, **Corey GR**, Heinle SK, Kisslo J. Positive and negative effects of transesophageal echocardiography on the Duke criteria for infective endocarditis. Forth-fifth Annual Scientific Session, American College of Cardiology Meetings Orlando, FL March 24-27, 1996.
  21. Abolnik IZ, Cleveland KO, Fahhoum JS, Abramson MA, **Corey GR**, Gelfand MS, Sexton DJ. Nosocomial fever of unknown origin (FUO). Sixth Annual Meeting of the Society of Healthcare Epidemiologists of America. Washington, DC, April 21-23, 1996.
  22. Marr KA, Schwab S, Sexton DJ, **Corey GR**, Conlon P, Kirkland K. Bacteremia in patients with central venous catheters used for hemodialysis. Thirty-sixth International Congress of Antimicrobial Agents



- and Chemotherapy. New Orleans, LA September 15-18, 1996.
23. Fowler VG, Boley J, Donovan CL, Li J, **Corey GR**, Sexton D, Marr KA, Gopal AK, Ryan T. Echocardiography in Patients with *Staphylococcus aureus* Bacteremia. 69th Scientific Session of the American Heart Association.
  24. Marr KA, Schwab S, Sexton DJ, **Corey GR**, Conlon P, Kirkland K. Bacteremia in Patients with Central Venous Catheters Used for Hemodialysis: Lack of Efficacy of Catheter salvage. ICAAC, 1996.
  25. Lim CS, Sexton DJ, Nettles R, **Corey GR**, Jollis JG, Fowler V, Donovan CL, Ryan T. Prospective Study of Clinical Outcome in Endocarditis Patients. American College of Cardiology Conference, 1997.
  26. Li, J, Nettles RE, McCarty DE, Fowler VG, Jr., Roe Mt, Ryan T, Sexton DJ, **Corey GR**. Clarification of the Duke Criteria for Infective Endocarditis. Fourth International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, Yverdon-les-Bains, Switzerland, May 1997.
  27. Fowler VG, Jr., Li J, Marr KA, Gopal AK, Kong L, Gottlieb G, Sexton DJ, Ryan T, Boley J, **Corey GR**. The Diagnosis of *Staphylococcus aureus* Endocarditis: A Relook at the Duke Criteria. Fourth International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, Yverdon-les-Bains, Switzerland May 1997.
  28. Fowler VG, Jr., Gopal AK, Kong L, Marr KA, Gottlieb G, McClelland RS, Sexton DJ, Ryan T, Boley J, **Corey GR**. *Staphylococcus aureus* Bacteremia: a Treatment Algorithm. 35<sup>th</sup> Annual Meeting, Infectious Diseases Society of America, San Francisco, USA. September 1997.
  29. Fowler VG, Jr., Sexton DJ, Kong L, Marr KA, Gopal AK, Gottlieb G, McClelland RS, **Corey GR**. Outcome of *Staphylococcus aureus* Bacteremia According to Compliance with Infectious Diseases Specialist Recommendations: Experience with 253 Patients. 35<sup>th</sup> Annual Meeting, Infectious Diseases Society of America, San Francisco, USA, September 1997.
  30. Kong L, Fowler VG, Jr., **Corey GR**, Gottlieb G, McClelland RS, Harrell E. Recurrent *Staphylococcus aureus* Bacteremia. 37<sup>th</sup> Annual Intersciences Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 1997.
  31. Swaim MW, Fowler VG, Jr., Gottfried M, Garbutt JT, **Corey GR**. An “Outbreak” of Mekongi-Species Schistosomiasis in Central North Carolina. Submitted, 1998.
  32. Bayer AS, Cheng D, Yeaman MR, **Corey GR**, McClelland RS, Harrell E, Fowler VG, Jr. In Vitro Resistance to Thrombin-Induced Platelet Microbicidal Protein Among Clinical Bacteremic Isolates of *Staphylococcus aureus* Correlates with an Endovascular Infectious Source. 38<sup>th</sup> Intersciences Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. September 1998
  33. Fowler VG, Jr., Sanders L, Kong L, Gottlieb GS, McClelland RS, Li J, Ryan T, Rousakas G, Sexton DJ, Harrell L, **Corey GR**. *Staphylococcus aureus* Endocarditis: 59 Prospectively Collected Cases with Follow up. 36<sup>th</sup> Annual Meeting, Infectious Diseases Society of America. Denver, Colorado. November 1998.
  34. Peterson GE, Fowler VG, Jr., Sexton DJ, **Corey GR**, Pond K, Li J, Donovan C, Ryan T. Timing of Echocardiographic Studies in Patients with *Staphylococcus aureus* Endocarditis: A Prospective Observational Study. Submitted 1999
  35. M. Stryjewski, MD, W. O’Riordan, MD, W. Lau, MD, F. Pien, MD, M. Vallee, V. Fowler, MD, V. Chu, MD, S. Barriere, Pharm D, **GR Corey**, MD. Telavancin (TLV) vs Standard Therapy (ST) for Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections (cSSTI). Submitted to IDSA, April 2004.

36. Efficacy and Safety of CEM-102 in a Phase 2, Randomized, Double-Blind Study in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)" ICAAC 2010 Susan Moriarty
37. Cessation of Antibiotic Prophylaxis for Dental Procedures and Incidence of Infective Endocarditis in the United Kingdom. Vivian Chu
38. Panton-Valentine Leukocidin (PVL) Is a key Determinant of Outcome in Patients with Hospital-Acquired Pneumonia (HAP) Due to Methicillin-Susceptible *Staphylococcus aureus* (MSSA) BK. Sharma-Kuinkel, ME Stryjewski, T Lalani, T Rude, MM Kitt, F Genter, HD Friedland, SL Barriere, **GR Corey**, VG Fowler Jr. ICAAC 2010
39. Vancomycin (VAN) serum trough levels (STL) and outcomes in patients with hospital-acquired pneumonia (HAP) due to *S. Aureus* (SA): the ATTAIN study. Dr. Corey, Dr. Rubinstein and Dr. Stryjewski. ECCMID 2010
40. Late ventilator-associated pneumonia (VAP): analysis of baseline characteristics and clinical outcomes in the ATTAIN studies.
41. A Single-Dose of Oritavancin (ORI) Is Comparable to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): the SOLO I Study. **R. Corey**, A. Perez, G. Moeck, H. Jiang, S. Good, SOLO I Investigators – ICAAC 2013
42. A Single-Dose of Oritavancin (ORI) Is Comparable to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): the SOLO II Study. **R. Corey**, A. Perez, G. Moeck, H. Jiang, S. Good, SOLO II Investigators – ICAAC 2013
43. In-Hospital and One Year Mortality in Patients Undergoing Early Surgery for Prosthetic Valve Endocarditis... therapy in the overall cohort. Tahaniyat Lalani, MBBS, MHS, Vivian Chu, MD, Lawrence Park, PhD, E Cecchi, MD, **G. Ralph Corey**, Emanuele Durante-Mangoni, Vance Fowler, Jr, MD MHS, David Gordon, Paolo Grossi, Margaret Hannan, MBBCh, MSc, PhD, Bruno Hoen, MD, Patricia ... – ID Week 2013
44. In-Hospital and One Year Mortality in Patients Undergoing Early Surgery for Prosthetic Valve Endocarditis. Tahaniyat Lalani, MBBS, MHS ; Vivian Chu, MD ; Lawrence Park, PhD ; E Cecchi, MD ; **G. Ralph Corey**; Emanuele Durante-Mangoni ; Vance Fowler, Jr, MD MHS ; David Gordon ; Paolo Grossi ; Margaret Hannan, MBBCh, MSc, PhD ; Bruno Hoen, MD ; Patricia Munoz ; Hussien Rizk, MD ; Souha Kanj, MD, FIDSA ; Christine Selton-Suty ; Daniel J. Sexton, MD, FIDSA; Denis Spelman, MBBS FRACP FRCPA MPH ; Veronica Ravasio, MD ; Marie-Françoise Tripodi, MD ; Andrew Wang, MD – ID Week 2013.
45. Concordance Between Early and Late Clinical Response with a Single Dose of Oritavancin in the SOLO Studies. **G. R. Corey**, S. Good, H. Jiang, G. Moeck, M. Wikler, SOLO I and SOLO II Investigators – ICAAC 2014
46. Efficacy and Safety Outcomes by Subgroups in Studies of a Single Dose of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). **G. R. Corey**, S. Good, H. Jiang, G. Moeck, M. Wikler – ICAAC 2014
47. Phase 3 Clinical Isolates with Reduced Susceptibility to Vancomycin Remain Susceptible to Telavancin. J. I. Smart, **G. Corey**, A. F. Shorr, M. E. Stryjewski, W. Wang, S. L. Barriere – ICAAC 2014
48. Interim Analysis of Ceftaroline Fosamil for the Treatment of *Staphylococcus aureus* Bacteremia. V. G. Fowler, Jr, H. Chambers, D. P. Levine, P. Cole, A. Jandourek, H. D. Friedland, **G. R. Corey** – ICAAC 2014
49. The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7–10 Days of Vancomycin

(VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) **Ralph Corey, MD**, Matthew Wikler, MD, FIDSA, Greg Moeck, Hai Jiang, Samantha Good And Solo I And II Investigators – ID Week 2014

50. Evaluation of Health-Related Quality of Life (HRQL) in ABSSSI Patients after Antibiotic Discontinuation in a Phase 3 Trial. **Corey R<sup>1</sup>**, Gupta K<sup>2</sup>, Henry E<sup>3</sup>, McGinnis E<sup>4</sup>, Cammarata S<sup>4</sup>
51. Ceftaroline Fosamil (CPT-F) in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with Systemic Inflammatory Signs: Results Across 3 Pivotal Studies Using q8h or q12h. Poster presented at ICAAC 9/19/15.
52. Randomized, double-blind, multicenter phase 2 study to evaluate efficacy and safety of intravenous Iclaprim (ICL) versus Vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associate pneumonia suspected or confirmed caused by gram-positive pathogens. Poster presented at ID Week 10/9/15.
53. Cessation of spread of lesion and absence of fever at 72 hours in complicated skin and skin structure infection (cSSSI): Reanalysis of the combined ASSIST phase III studies comparing Iclaprim (ICL) and Linezolid (LZD). Poster presented at ID Week 10/9/15.
54. In vitro activity of eravacycline and comparators against *Acinetobacter baumannii*, including carbapenem-resistant strains, and *Stenotrophomonas maltophilia* isolated from patients in the US. Doi Y, **Corey GR**, Morrissey I, Grossman T, Luepke K, Scoble P, Sutcliffe J. Poster presented at ASM Microbe 2016 Boston, MA.
55. In vitro activity of eravacycline and comparators against Enterobacteriaceae, including strains resistant to carbapenems or 3<sup>rd</sup>/4<sup>th</sup> generation cephalosporins in the US. Doi Y, **Corey GR**, Morrissey I, Grossman T, Luepke K, Scoble P, Sutcliffe J. Poster presented at ASM Microbe 2016 Boston, MA.
56. Eravacycline In Vitro Activity Against Clinical Isolates Obtained from Genitourinary (GU) and Gastrointestinal (GI) Sources from Patients in the United States. **Corey GR**, Doi Y, Morrissey I, Grossman T, Olesky M, Patel H, Sutcliffe J. Poster presented at ASM Microbe 2016 Boston, MA.
57. *In vitro* global surveillance of eravacycline and comparators against *Staphylococcus* spp. And *Enterococcus* spp. Over a three-year period (2013-15). Basetti M, **Corey GR**, Doi Y, Morrissey I, Grossman T, Olesky M, Sutcliffe J. Poster presented at ID Week 2016, New Orleans, LA.
58. *In vitro* global surveillance of eravacycline and comparators against Enterobacteriaceae, *Acinetobacter baumannii*, *Stenotrophomonas maltophilia*, including multidrug-resistant (MDR) isolates, over a three-year period (2013-15). Basetti M, **Corey GR**, Doi Y, Morrissey I, Grossman T, Olesky M, Sutcliffe J. Poster presented at ID Week 2016, New Orleans, LA.

#### Submitted Abstracts:

##### Editorials, position, and background papers:

1. Dodds AG, Abramson MA, **Corey GR**, Kisslo J, Sexton DJ. Utility of the Duke criteria for infective endocarditis (letter) Clin Infect Dis 21:448, 1995.
2. Telithromycin. Annals of Internal Medicine, March 2006, (144) 447-448.
3. Reply to Solnick et al. Ralph Corey; Martin E. Stryjewski. Clinical Infectious Diseases 2015; doi: 10.101093/cid/civ372. PMID: 25956892.

4. Vancomycin-resistant *Enterococcus faecium* prosthetic valve endocarditis treated with oritavancin: a case report and review of the literature. Erin R. Feeney, Jennifer A Johnson, Greg Moeck, Samantha Good, G. Ralph Corey.

**Consultant appointments:** Durham Regional Hospital, Durham NC (Consultative staff) 1996 - 2007  
 Duke University Medical Center, Durham NC (Active staff), 1983-present  
 Durham Veterans Administration Hospital, Durham, NC 2008- present  
 Federal Prison in Butner, NC (Consultative staff) 2001-2003

**Advisory Boards & Committees /Consultant**

Vicuron	Cerexa / Forest/Actavis	Synereca
Inhibitex	Polymedix	Theravance
Cubist – Chair	Rib-X/Melinta	Paratek
ISCVID	Cempra	SC Pharma
Medacorp	Durata	Tetraphase
Clinical Advisors	Nabriva	Arsanis
Innocol	Ampliphi	Basilea
Merck	AstraZeneca	Bayer
Pfizer	Astellas	Bio2
Johnson and Johnson	Achaogen	Inimex
Inimex	Contrafect	Medtronic
GSK	Gilead	Motif
Trius	Dr. Reddy’s Lab	
The Medicines Company	Seachaid	

**Grand Round / Presentations**

October 2005 – Medicine Grand Rounds at Duke Medical Center  
 November 2005 – Grand Rounds at UVa on Leishmania  
 Indiana University – 2005 – Staphylococcus bacteremia  
 Mt Sinai, NY –2007 - Global Health  
 University of Nebraska – Global Health  
 Internations Society of Cardiovascular Infectious Diseases  
 ICAAC – multiple presentations  
 IDSA – multiple presentations  
 Visiting Professor – MGH, Washington U, IU, Neb, Universidade Federal do Espirito SantoFES, Hospital Clinicas, Barcelona, Beijing Hospital, Beijing, Sun Yat Sen Medical Center,Taiwan, Mt. Sinai, NY

**Professional awards and special recognitions:**

Housestaff Teaching Award, 1978  
 Senior Staff Teaching Award, 1982  
 Family Medicine Teaching Award, 1983  
 Basic Sciences Teaching Award, 1996

Housestaff Teaching Award, 1999  
Robert J. Glaser Clinical Stars Program, WU, 2001  
Arthur E. Palumbo Award, Duke 2001  
Distinguished Alumni Award, Duke 2004  
Duke University Research Mentoring Award, Duke 2010  
2012 Friendship Award (State Administration of Foreign Experts Affairs, Peoples Republic of China)  
Presented by Premier of PRC Wen  
2014 Walter E. Stamm Mentor Award, presented by the Infectious Diseases Society of America  
(IDSA) annual meeting  
2015 Alumnus of the Year, Baylor College of Medicine

**Organizations and participation:**

Fellow, American College of Physicians  
Fellow, Infectious Diseases Society of America  
Member, Nominations Committee  
International Society of Cardiovascular Infections Diseases  
Subcommittee on Scientific Projects

Editorial Board: *Clinical Infectious Diseases*

Reviewer: *Clinical Infectious Diseases*  
*Chest*  
*Journal of the American Society of Tropical Medicine and Hygiene*  
*Journal of the American Medical Association*  
*American Journal of Cardiology*  
*Up to Date Electronic Journal*  
*Antimicrobial agents and chemotherapy*

Minority International Research Training Program  
Association of Program Directors in Internal Medicine 1984-2002  
Member Academic Council 2000, 2001

**Clinical Responsibilities**

Attending, Infectious Diseases Division Consult Service, Durham VAH 2 months per year  
Attending, General Medicine, Durham VAH 1 month per year  
Facilitator, Morning Report, 100 times per year  
Weekly Infectious Diseases Clinic, Duke Hospital

**Teaching/Mentoring responsibilities:**

Having stepped down as the Program Director of the Internal Medicine Residency Training Program after 18 years, I then focused my efforts on directing clinical research at the Duke Clinical Research Institute as well as participating in Infectious Disease rounds (2 months per year) as well as General Medicine rounds (1 month per year), caring for patients in the Infectious Disease clinic and establishing a Center for Global Health. All

of these efforts involve teaching and mentoring housestaff.

My work at the DCRI focused on multi-center, international trials. With the help of four fellows (sequentially) who were training in clinical research techniques we direct these trials from their inception (protocol development) to their completion and presentation. All of this requires a tremendous amount of time and effort both for the trials and for the mentoring and sub-study development necessary for fellow experience.

Infectious Disease rounds involved students, residents, and fellows where further teaching and mentoring can and does occur. This effort does involve a considerable amount of my time but results in the stimulation of housestaff and the creation of clinical research projects. Clinic likewise often involves fellows and the solving of problems and answering of questions through literature searches.

Finally, my work in the Global Health arena blossomed. Not only did I provide lectures for the first year medical students but in addition we have been able to send over 300 residents overseas for 3 month rotations at sites that I have established. Finally, I have been able to obtain agreements for endowments worth over 9 million dollars and am now the Director of the Hubert/Yeargan Center for Global Health. This Center focuses on the training of global health fellows who hopefully one day would develop careers in global health and basic science research. It also supports the research with service that is undertaken in Africa and South America.

## **Contribution to Science**

1. My original research efforts targeted *S. aureus* bacteremia (SAB). With the help of 3 interns we focused on defining uncomplicated and complicated bacteremia we attempted to identify criteria which would allow abbreviated therapy. Investigating the value of transesophageal echocardiography, the importance of follow-up blood cultures, the risk of both intra- and extra-vascular prosthetic material, the frequency of infected thrombophlebitis and prolonged bacteremia in patients with central lines, and the accuracy of defining recurrence using pulsed-field gel electrophoresis we were able to create an algorithm to assist clinicians with this frequent and important decision. In addition, we were able to study many other important issues such as risk of catheter salvage in patients with SAB, the outcome of patients on dialysis who acquired SAB, the importance of SAB in post-median-sternotomy patients, the influence of age, diabetes, and neutropenia on the outcome of SAB, inoculum effect on outcomes, attachment force differences between bacteremia producing and colonizing *S. aureus*, and clonal differences in the risk of complications (e.g. IE) of SAB.
  - a. Rosen, AB, Fowler, VG, Jr., **Corey, GR**, Downs, SM, Biddle, AK, Li, J, Jollis, JG. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated *Staphylococcus aureus* bacteremia. *Annals of Internal Medicine*. 130(10): 810-20, May 18, 1999. PMID:10366370.

- b. Fowler VG Jr. Sakoulas G. McIntyre LM. Meka VG. Arbeit RD. Cabell CH. Stryjewski ME. Eliopoulos GM. Reller LB. **Corey GR**. Jones T. Lucindo N. Yeaman MR. Bayer AS. Persistent bacteremia due to methicillin-resistant *Staphylococcus aureus* infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. [Journal Article. Research Support, U.S. Gov't, P.H.S.] *Journal of Infectious Diseases*. 190(6):1140-9, 2004 Sep 15. PMID:15319865.
  - c. Chamis, AL, Cabell, CH, Peterson, GE, **Corey, GR**, Sorrentino, RA, Ryan, T, Reller LB, Fowler, VG Jr. *Staphylococcus aureus* bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. *Circulation*. 104(9): 1029-33, Aug. 28, 2001. PMID:11524397.
  - d. Fowler, Vance G. Jr MD, MHS; Olsen, Maren K. PhD; **Corey, G. Ralph MD**; Woods, Christopher W. MD, MPH; Cabell, Christopher H. MD; Reller, L. Barth MD; Cheng, Allen C. MB, BS; Dudley, Tara MS; Oddone, Eugene Z. MD, MHS Clinical Identifiers of Complicated *Staphylococcus aureus* Bacteremia. *Archives of Internal Medicine*. 163(17):2006-2072, September 22, 2003. PMID:14504120.
2. Continuing the work on *S. aureus* (with Vance Fowler) I then created the International Collaboration on Endocarditis (ICE). Again with the help of residents/fellows (e.g. Vivian Chu) this rapidly growing clinical research collaboration, funded primarily with good will of the 300+ investigators, focused on the changing epidemiology of IE as well as the important clinical problems such as the importance of early surgery, the risk of valve replacement in patients suffering from embolic strokes, the risk of renal failure, the frequency of IE in infants and children, the epidemiology, clinical characteristics and outcome in a variety of pathogens causing IE (e.g. enterococcus, HACEK, gram negative bacilli, and candida), and the management of prosthetic valve IE.
- a. Wang A., Athan E., Pappas P., Fowler V., Olaison L., Pare C., Almirante B., Munoz P., Rizzi M., Naber C., Logar M., Tattevin P., Iarussi D., Seton-Suty C., Jones S., Casabe J., Morris A., **Corey GR.**, Cabell CH. International Collaboration on Endocarditis-Pro prospective Cohort Study Investigators. Contemporary clinical profile and outcome of prosthetic valve endocarditis. *JAMA* 2007 Mar 28;297(12):1354-61. PMID:17392239.
  - b. Chu, Vivian H. MD Cabell, Christopher H. MD; Benjamin, Daniel K. Jr MD, MPH, PhD; Kuniholm, Erin F. MD, MPH; Fowler, Vance G. Jr MD, MHS; Engemann, John MD; Sexton, Daniel J. MD; **Corey, GR MD**; Wang, Andrew MD. Early Predictors of In-Hospital Death in Infective Endocarditis. *Circulation* 109(14):1745-1749, April 13, 2004.
  - c. Chu VH. Cabell CH. Abrutyn E. **Corey GR**. Hoen B. Miro JM. Olaison L. Stryjewski ME. Pappas P. Anstrom KJ. Eykyn S. Habib G. Benito N. Fowler VG Jr. International Collaboration on Endocarditis Merged Database Study Group. Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. *Clinical Infectious Diseases*. 39(10):1527-30, 2004 Nov 15. PMID:15546091.
  - d. McDonald JR. Olaison L. Anderson DJ. Hoen B. Miro JM. Eykyn S. Abrutyn E. Fowler VG Jr. Habib G. Selton-Suty C. Pappas PA. Cabell CH. **Corey GR**. Marco F. Sexton DJ. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. [Comparative Study. Journal Article. Multicenter Study. Research Support,

N.I.H., Extramural. Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.] American Journal of Medicine. 118(7):759-66, 2005 Jul. PMID:15989910.

- e. Anderson DJ. Olaison L. McDonald JR. Miro JM. Hoen B. Selton-Suty C. Doco-Lecompte T. Abrutyn E. Habib G. Eykyn S. Pappas PA. Fowler VG. Sexton DJ. Almela M. **Corey GR**. Cabell CH. Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from the International Collaboration on Endocarditis-merged database. European Journal of Clinical Microbiology & Infectious Diseases. 24(10):665-70, 2005 Oct. PMID:16244853.

3. In 2002 I moved to the Duke Clinical Research Institute as director of infectious diseases research. As a result my focus shifted to the design, management and outcome of large clinical trials involving new antibiotics/immunoglobulins, vaccines in patients with skin and skin structure infections (both treatment and prevention), device infection prevention trials (pacemakers and intravascular umbrellas), pneumonia (both community and hospital acquired), blood stream infections, etc. Seminal trials involving daptomycin, telavancin, ceftaroline, tefibazumab, fusidic acid, solithromycin, anti-staphylococcal vaccine, tedizolid, and oritavancin.

- a. Fowler VG Jr. Boucher HW. **Corey GR**. Abrutyn E. Karchmer AW. Rupp ME. Levine DP. Chambers HF. Tally FP. Vigiiani GA. Cabell CH. Link AS. DeMeyer I. Filler SG. Zervos M. Cook P. Parsonnet J. Bernstein JM. Price CS. Forrest GN. Fatkenheuer G. Gareca M. Rehm SJ. Brodt HR. Tice A. Cosgrove SE. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. N Eng J Med 2006 Aug 17; 355(7):653-65. PMID:16914701.
- b. **Corey GR**, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riordan W for SOLO II Investigators. Single-dose Oritavancin compared to 7-10 days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: the SOLO II Non-inferiority study. *Clin Inf Dis*. 2014 Oct 6. pii: ciu778. [Epub ahead of print] PMID: 25294250.
- c. Bennett-Guerrero E, Pappas T, Koulton W, Fleshman J, Lin M, Garg J, Mark D, Marcet J, Remzi F, George V, Newland K and **Corey GR**, for the Swipe-2 Trial Group. Gentamicin-Collagen Sponge for Infection Prophylaxis in Colorectal Surgery. New England Journal of Medicine. 363(11):1038-49, 2010 Sep 9. PMID:20825316.

4. During my entire career I have focused on mentoring young potential clinical researchers. Nearly half my publications are written by these incredibly talented physicians, most of whom have gone on to be successful independent researchers. As a result I have won mentoring awards from Duke University and the Infectious Diseases Society of America.

## Clinical Research

Principal Investigator, DCRI

1. Fast I with Theravance, Inc
2. Fast II with Theravance, Inc
3. Assure with Theravance, Inc
4. Atlas I with Theravance, Inc



5. Atlas II with Theravance, Inc
6. Attain I with Theravance, Inc
7. Attain II with Theravance, Inc
8. TD1792 with Theravance, Inc
9. Fever Study with Inhibitex, Inc
10. Blood Stream Infection with Inhibitex
11. Surgical Wound Infection Prevention, Innocoll
  - a. Swipe I
12. Surgical Wound Infection Prevention, Innocoll
  - a. Swipe 2
13. Surgical Wound Infection Prevention, Dr. Reddy's Lab
14. Solo I ABSSSI Trial, The Medicines Company
15. Solo II ABSSSI Trial, The Medicines Company
16. Canvas I ABSSSI trial, Cerexa
17. Canvas II ABSSSI trial, Cerexa
18. Fusidic Acid ABSSSI trial, Cempra
19. Solithromycin CAP trial I, Cempra
20. Solithromycin CAP trial II, Cempra
21. Daptomycin bacteremia trial, Cubist
22. Tedizolid skin trial, Trius
23. Zepher trial, Pfizer
24. GSK 322 ABSSSI trial, GSK
25. Staph vaccine trial, Merck
26. ANGEL Trial – pulmonary embolism prevention – BiO2 Medical
27. WRAPPIT Trial – pacemaker infection prevention – Medtronic

**Present Clinical Research Endeavors by Dr. Corey**

1. Staph Aureus Bacteremia Group
2. International Collaboration on Endocarditis
3. Numerous clinical trial involving patients with skin, lung, bloodstream and joint infections.
4. Education/Mentoring: As a result of my position as Vice-Chair of Education and Global Health for the Department of Medicine I enjoy finding new ways to train physicians on the wards and in the outpatient clinics as well as in the clinical research arena. Global Health continues to consume time and energy as we continue our research and educational efforts in Kenya, Tanzania, Rwanda, Nicaragua, Brazil, Haiti, China, Thailand, Sri Lanka, India, and the Indian Health Service. In addition, we have developed a GH residency/fellowship pathway where residents and fellows obtain a masters in GH as well as spending 9 months overseas.